AUTHOR INDEX

(P = proceedings)

ABEL, S. M., MAGGS, J. L., BACK, D. J. NEWBY, S., COLBERT, J. & PARK, B. K. Cortisol metabolism by human liver *in vitro*, 231P

ABERNETHY, L. & HAWKSWORTH, G. M. Cytochrome P450-dependent activity and intracellular nucleotide levels in post-cryopreserved rat hepatocytes, 228P

ABRAMS, S. M. L. Book review: Neurotransmitters and drugs. By Z. L. Kruk & C. J. Pycock, 210

ABRAMS, S. M. L. *see* GRIFFITHS, E.

ACTON, G. *see ROSE, J.*

ADAIR, C. G., MCCALLION, O., MCELNAY, J. C., SCOTT, M. G. HAMILTON, B. A., MCCANN, J. P., STANFORD, C. F. & NICHOLLS, D. P. A pharmacokinetic and pharmacodynamic comparison of plain and enteric-coated prednisolone tablets, 495

AISLAITNER, G. & GORROD, J. W. The *in vitro* metabolism of anabasine and methyl anabasine, 230P

AKINGBEHIN, T. *see* WALLEY, T.

ALDIGIER, J. C. *see* BEVAN, E. G.

ALESSANDRINI, P. *see* BARROW, S. E.

ALHALEL, A. *see* ZIV, I.

ALI, A. *see* SENNESAEL, J.

ALKALAY, M. *see* ZIV, I.

ALLEN, G. D. *see* BRETT, M. A.

ALLEN, G. D. *see* KÖSTER, F. E.

ALLEN, M. E. & VANDENBURG, M. J. Good clinical practice: rules, regulation and their impact on the investigator, 463

ALMOG, S. *see* ZIV, I.

ALVES, F. *see* LÖSER, C. H. R.

ANDERER, P. *see* SALETU, B.

ANDERSEN, M. *see* HALLAS, J.

ANDERSON, V. *see* SILKE, B.

ANDREASEN, F., ERIKSEN, U. H., GUUL, S.-J., NIELSEN, L. P., BECH, O. M., DIAMANT, B., KAHR, O., BRUUN, P., HARTLING, O. J. & HVIDT, S. A comparison of three diuretic regimens in heart failure, 224P

ANKIER, S. I. *see* CROME, P.

ANKIER, S. I. *see* WARRINGTON, S. J.

ARANKO, K. *see* MATTILA, M. J.

ARANKO, K., OLKKOLA, K. T., HILLER, A. & SAARNIVAARA, L. Clinically important interaction between erythromycin and midazolam, 217P

ARCHER, C. B. & KAVANAGH, G. M. Effects of human serum albumin on PAF- and histamine-induced inflammatory responses in the skin of normal and atopic subjects, 567P

ARCHER, C. B., BURTON, J. L. & MARSHMAN, G. Effects of intradermal kalladin and bradykinin in normal subjects and patients with psoriasis, 566P

ARCHER, C. B., DOLLERY, C. T., SANSOM, J. E. & TAYLOR, G. W. Urinary leukotriene E4 levels in severe atopic dermatitis, 566P

ARNOLD, J. D., WILLIAMS, G. T., WILKINS, W. E., MORRIS, J. S., RHODES, J. & WOODHOUSE, K. W. Large intestinal inflammation associated with oral non-steroidal anti-inflammatory drug ingestion, 240P

ARVELA, P. *see* HONKAKOSKI, P.

ASHAN, C. H., RENWICK, A. G., CHALLENOR, V. F., WALLER, D. G. & GEORGE, C. F. The influences of dose and ethnic origins on the pharmacokinetics of nifedipine after oral administration as capsules, 214P

ASK, B. *see* RANE, A.

ASQUITH, P. A. *see* MARRIOTT, J. F.

ATKINSON, H. C. *see* BEGG, E. J.

BAAK, L. C., GANESH, S., JANSEN, J. B. M. J. & LAMERS, C. B. H. W. Dose smoking influence the pharmacokinetics and pharmacodynamics of the H_2-receptor antagonist famotidine? 193

BABER, N. S. *see* HALL, S. T.

BABER, N. S. *see* MACKAY, J.

BABER, N. S. *see* MOORE, K.

BACK, D. J. *see* ABEL, S. M.

BACK, D. J. *see* HOWE, J. L.

BACK, D. J. *see* WEBBER, I. R.

BACK, D. J. *see* WILD, M. J.

BACK, D. J., ORMESHER, S., TIJA, J. F. & MACLEOD, R. Metabolism of 2′3′-dideoxyinosine (ddI) in human blood, 319

BADCOCK, N. R. *see* WATKINS, D. N.

BADENHORST, P. N. *see* MEYER, B. H.

BAILEY, R. R. *see* ROBSON, R. A.

BALDERSON, D. E., HARRON, D. W. G., O'KEEFE, B., MITCHELL, R. H. & ESCALONA, O. Incidence of late potentials (LP) depends on the method of assessment in patients following myocardial infarction, 563P

BAMMEL, A., NOKHODIAN, A., SANTOS, S. R. C. J. & KIRCH, W. Digitoxin metabolites in liver cirrhosis, 550P

BARHAM, H. M., LENNARD, M. S., TUCKER, G. T. & WOODS, H. F. Impaired metabolism of lignocaine in the female DA rat, 234P

BARNES, P. J. *see* VENTRESCA, P. G.

BARNETT, D. *see* CHESTER, M. R.

BARNETT, D. B. *see* CAHILL, M.

BARROW, S. E., KONTESSIS, P. S., JONES, S. L., ALESSANDRINI, P., DE COSMO, S., RITTER, J. M. & VIBERTI, G.-C. Effects of selective inhibition of thromboxane biosynthesis on renal function in insulin-dependent diabetic patients with nephropathy, 562P

BASCO, L. K., GILLOTIN, C., GIMENEZ, F., FARINOTTI, R. & LE BRAS, J. *In vitro* activity of the enantiomers of mefloquine, halofantrine and enpiroline against *Plasmodium falciparum*, 517

BECH, O. M. *see* ANDREASEN, F.

BECK-NIELSEN, J. *see* HALLAS, J.

BEGAUD, B. *see* TUBERT, P.

BEGG, E. J., ATKINSON, H. C. & DUFFULL, S. B. Prospective evaluation of a model for the prediction of milk:plasma drug concentrations from physicochemical characteristics, 501

BEGLINGER, C. *see* DREWE, J.

BENCH, C. *see* GRASBY, P.

BENTLEY, P. H. *see* GREAVES, J. L.

BERTOLINE, M. A. *see* SANTOS, S. R.

BEVAN, E. G., MCINNES, G. T., ALDIGIER, J. C., CONTE, J. J., FEEHALLY, M. J., GRUNFELD, J. P., MEYER, B. H., PAULY, N. & WILKINSON, R. Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril, 237P

BEVAN, E. G., MURDOCH, D. L., FINDLAY, J. G., MURRAY, G. D. & MCINNES, G. T. Antihypertensive efficacy of cicletanine 50 mg daily assessed by ambulatory blood pressure monitoring, 530P

BHATT, S. B. *see* TOMLINSON, B.

BIRGER JENSEN, K. *see* HALLAS, J.

BIRGERSDOTTER, U. M., WONG, W., TURGEON, J. & RODEN, D. M. Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias, 275

BIRMINGHAM, A. T. *see* GREAVES, J. L.

BLACK, I. *see* GLOVER, D. R.

BLACKLAW, J. *see* MCKEE, P. W. J.

BLANCHARD, J., HARVEY, S. & MORGAN, W. J. Variability of the

serum protein binding of theophylline in patients with asthma and cystic fibrosis, 653
BLANKSON, E. A., ELLIS, S. W., LENNARD, M. S., TUCKER, G. T. & ROGERS, K. Tamoxifen metabolism in human liver microsomes is not mediated by cytochrome P4502D6, 234P
BLASCHKE, T. F. *see* FORD, G. A.
BLAUW, G. J. *see* BRUNING, T. A.
BLEE, M. A. B. *see* TINGLE, M. D.
BLOOMER, J. C., WOODS, F. R., HADDOCK, R. E., LENNARD, M. S. & TUCKER, G. T. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes, 521
BLOOMER, J. C., WOODS, F. R., HADDOCK, R. E., LENNARD, M. S. & TUCKER, G. T. The role of cytochrome P450IID6 in the metabolism of paroxetine by human liver microsomes, 227P
BOEIJINGA, J. K. *see* COHEN, A.
BOEIJINGA, J. K., BREIMER, D. D., KRAAY, C. J. & KLEINBLOESEM, C. H. Absence of interaction between the ACE inhibitor cilazapril and coumarin derivatives in elderly patients on long term oral anticoagulants, 553P
BONDESSON, U. *see* QUIDING, H.
BOOBIS, A. R. *see* EDWARDS, R. J.
BOOBIS, A. R. *see* MURRAY, B. P.
BOOBIS, A. R. *see* RICH, K. J.
BOOTH, T. G. *see* NEWTON-SMITH, F. A. O.
BOREUS, L. O. *see* QUIDING, H.
BOURNE, M., SZABADI, E. & BRADSHAW, C. M. Comparison of amoxapine and amitriptyline on autonomic functions in healthy volunteers, 570P
BOWES, S. G. *see* O'NEILL, C. J. A.
BOWES, S. G., CARLETT, A., MEHTA, R., LUBEL, D., DOBBS, S. M., WELLER, C., O'NEILL, C. J. A. & DOBBS, R. J. Relative importance of treatment and other variables in determining free walking speed in idiopathic parkinsonism, 246P
BOWES, S. G., DOBBS, R. J., HEALEY, M., CHARLETT, A., O'NEILL, C. J. A., WELLER, C. & DOBBS, S. M. Response of gait to an acute challenge with Sinemet CR before and during its use as maintenance anti-Parkinsonism therapy, 569P
BRADSHAW, C. M. *see* BOURNE, M.
BRADSHAW, C. M. *see* LEUNG, N. K.-C.
BRADSHAW, C. M. *see* THEOPHILOPOULOS, N.
BRADSHAW, C. M. LEUNG, N. K.-C. & SZABADI, E. Effect of high ambient temperature on the kinetics of the pupillary light reflex, 549P
BRAIN, S. D. *see* SCIBERRAS, D. G.
BRAIN, S. D., THOMAS, G., CROSSMAN, D. C., FULLER, R. & CHURCH, M. K. Endothelin-1 induces a histamine-dependent flare *in vivo*, but does not activate human skin mast cells *in vitro*, 117
BRATER, D. C. *see* KNADLER, M. P.
BRATER, D. C. *see* MURRAY, M. D.
BRAUNSTEIN, G., MALAQUIN, F., FAJAC, I., MELAC, M. & FROSSARD, N. Inhibition of histamine-induced nasal obstruction by cetirizine in allergic rhinitis, 445
BRECKENRIDGE, A. M. *see* NG, H. W. K.
BRECKENRIDGE, A. M. *see* PIRMOHAMED, M.
BRECKENRIDGE, A. M. *see* SCOTT, A. K.
BRECKENRIDGE, A. M. *see* WALLER, P. C.
BREIMER, D. D. *see* BOEIJINGA, J. K.
BRENNAN, G. M., MCVEIGH, G. E., JOHNSTON, G. D. & HAYES, J. R. Dietary fish oil augments EDRF production or release in patients with non-insulin dependent diabetes mellitus, 531P
BRETT, M. A., HOETZEL, L., PFEIFFER, P., ALLEN, G. D., HOLLIS, F. J., THAWLEY, A. R. & GULATI, R. Investigation of the single and repeat dose oral pharmacokinetics of denbufylline in healthy young and elderly subjects, 235P
BRIDGES, A., STIRLING, H., MCDOWELL, J., JENSEN, S., JORGENSEN, J. T. & KELNAR, C. Double-blind study to compare the local tolerance of three different solvents used to reconstitute growth hormone, 563P
BRIDGMAN, P. G. *see* ROBSON, R. A.
BROCHWICZ-LEWINSKI, M. J. *see* NG, L. L.
BRODDE, O.-E., HUNDHAUSEN, H.-J., ZERKOWSKI, H.-R. & MICHEL, M. C. Lack of effect of chronic calcium antagonist treatment on β_1- and β_2-adrenoceptors in right atria from patients with or without heart failure, 269
BRODIE, M. J. *see* LARKIN, J. G.
BRODIE, M. J. *see* MCKEE, P. W. J.
BROSEN, K. *see* HALLAS, J.
BROUWER, O. F. *see* PIETERS, M. S. M.
BROWN, T. M. *see* HORTON, R. C.
BRUNING, T. A., CHANG, P. C., BLAUW, G. J. & VAN ZWIETEN, P. A. Vasoconstrictor responses to noradrenaline and angiotensin II are not influenced by 5-HT in the human forearm, 554P
BRUUN, P. *see* ANDREASEN, F.
BRYSON, S. *see* GLOVER, D. R.
BURGGRAAF, J., SCHALIJ, M. J., GOLDBERG, M. R., PORRAS, A., DESMET, M. & COHEN, A. F. L-691,121, a novel class III antiarrhythmic: first administration in man, 532P
BURKE, M. D. *see* NEWLANDS, A. J.
BURTON, J. L. *see* ARCHER, C. B.
BUSS, N. E. & RENWICK, A. G. The timecourse and plasma concentrations-effect relationship for hypertension in rats infused with cyclohexylamine, the active metabolite of cyclamate, 238P

CAHILL, M., MISTRY, R. & BARNETT, D. B. The human platelet fibrinogen receptor: clinical and therapeutic significance, 3
CAHILL, M., MISTRY, R., CHAPMAN, C., WOOD, J. K. & BARNETT, D. B. Effects of age, sex and the oral contraceptive on platelet membrane fibrinogen binding site (Glycoprotein IIb/IIa), 11
CALVERT, R. T. *see* NEWTON-SMITH, F. A. O.
CAMERON, D. W. *see* SAHAI, J.
CAMPBELL, L. M. *see* GROOM, P. J.
CAMPBELL, N. R. C., KARA, M., HASINOFF, B. B., HADDARA, W. M. & MCKAY, D. W. Norfloxacin interaction with antacids and minerals, 115
CARRAI, M. *see* VIANI, A.
CEUPPENS, P. R. *see* PRESTON, G. C.
CHALLENOR, V. F. *see* ASHAN, C. H.
CHAN, J. C. N., CRITCHLEY, J. A. J. H., COCKRAM, C. S., NICHOLLS, M. G. & SWAMINATHAN, R. Effects of an ACE inhibitor and calcium channel blocking agent in proteinuria and plasma vasoactive hormone concentrations in hypertensive patients with NIDDM, 242P
CHANG, P. C. *see* BRUNING, T. A.
CHAPMAN, C. *see* CAHILL, M.
CHARLETT, A. *see* BOWES, S. G.
CHARLETT, A. *see* O'NEILL, C. J. A.
CHATELLIER, G. *see* CHAUVEAU, D.
CHAUVEAU, D., GUYENNE, T. T., CUMIN, F. CHATELLIER, G., CORVOL, P. & MENARD, J. Investigations of the biochemical effects of renin inhibition in normal volunteers treated by ACE inhibitor, 253
CHESTER, A. H. *see* LUU, T. N.
CHESTER, M. R., MADDEN, B., BARNETT, D. & YACOUB, M. The effect of orthotopic transplantation

on total, β_1- and β_2-adrenoceptors in the human heart, 417
CHEVALIER, P. *see* CROME, P.
CHIBA, K. *see* SETIABUDY, R.
CHILTON, J. E. *see* MINTON, N. A.
CHIN, J. *see* SHEN, A.
CHRISTENSEN, N. J. *see* KELBÆK, H.
CHURCH, M. K. *see* BRAIN, S.D.
CLAGUE, J. *see* SPRING, J.
CLARE, C. *see* VENTRESCA, G. P.
CLARKE, R. S. J. *see* FEE, J. P. H.
CLEFFMANN, U. *see* LÖSER, C. H. R.
COAKLEY, D. *see* MCCORMACK, P.
COAKLEY, D. *see* O'NEILL, D. O.
COATES, P. J. *see* PALMER, C. N. A.
COCKRAM, C. S. *see* CHAN, J. C. N.
COHEN, A., BOEIJINGA, J. K., VAN HAARD, P. M. M., SCHOEMAKER, R. C. & VAN VLIET-VERBEEK, A. Gastrointestinal blood loss after non-steroidal anti-inflammatory drugs. Measurement by selective determination of faecal porphyrins, 33
COHEN, A. F. *see* BURGGRAAF, J.
COHEN, A. F. *see* KROON, C.
COHEN, A. F. *see* PIETERS, M. S. M.
COHEN, A. F. *see* PIJL, H.
COHEN, A. F. *see* VAN GRIENSVEN, J. M. T.
COHEN, A. F. *see* VAN STEVENINCK, A. L.
COLBERT, J. *see* ABEL, S. M.
COLBERT, J. *see* HOWE, J. L.
COLEMAN, M. D. *see* TINGLE, M. D.
COLLIER, P. S. *see* FEE, J. P. H.
CONNELL, J. M. C. *see* MORRIS, A. D.
CONTE, J. J. *see* BEVAN, E. G.
COOKE, J. *see* NEWTON-SMITH, F. A. O.
COOKE, T. *see* FEELY, J.
CORVOL, P. *see* CHAUVEAU, D.
COSTELLO, J. F. *see* SAMPSON, A. P.
COUTIFARIS, C. *see* FREEMAN, E. W.
COWEN, P. *see* GRASBY, P.
CRITCHLEY, J. A. J. H. *see* CHAN, J. C. N.
CRITCHLEY, J. A. J. H. *see* TOMLINSON, B.
CRITCHLEY, M. *see* SCOTT, A. K.
CROME, P., WIJAYAWARDHANA, P., ANKIER, S. I., DOWELL, P., CHEVALIER, P. & GUILLET, P. The pharmacokinetics of suriclone following single and multiple dose administration in healthy elderly volunteers, 550P
CROSSMAN, D. C. *see* BRAIN, S. D.
CROWE MCCANN, C., GOLDFARB, B., FRISK, M., QUERA-SALVA, M. A. & MEYER, P. The role of personality factors and suggestions in placebo effect during mental stress test, 107
CULLEN, M. *see* FEELY, J.
CUMIN, F. *see* CHAUVEAU, D.
CUTHILL, A. R. *see* GROOM, P. J.
DAMSBO, M. *see* HALLAS, J.
DANDONA, P. *see* GILL, J.
DART, A. *see* SHEN, A.
DASHWOOD, M. R. *see* LUU, T. N.
DASHWOOD, M. R., THEODOROPOULOS, S., SPATENKA, J. & MUDDLE, J. R. [^{125}I]-endothelin-3 binding to human blood vessels: possible vascular effects of ET-3, 529P
DAVIDSEN, O. *see* HALLAS, J.
DAVIES, D. S. *see* RICH, K. J.
DAVIES, J. E. *see* NG, L. L.
DAVIES, S. *see* PALMER, C. N. A.
DAWSON, P. H. *see* NEWTON-SMITH, F. A. O.
DE BERSAQUES, J. *see* MEYER, E.
DE BOER, A. *see* KROON, C.
DE BROE, M. E. *see* HALL, S. T.
DE COSMO, S. *see* BARROW, S. E.
DE LEENHEER, A. *see* MEYER, E.
DE MEY, C. & MEINEKE, I. Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA), 179
DEBBAS, N. *see* WARRINGTON, S.
DELLA PASCHOA, O. E. *see* SANTOS, S. R.
DEN HARTIGH, J. *see* VAN STEVENINCK, A. L.
DESCHE, P. *see* SENNESAEL, J.
DESHMUKH, A. A. *see* O'NEILL, C. J. A.
DESMET, M. *see* BURGGRAAF, J.
DEWLAND, P. M. *see* RAPEPORT, W. G.
DIAMANT, B. *see* ANDREASEN, F.
DOBBS, R. J. *see* BOWES, S. G.
DOBBS, R. J. *see* O'NEILL, C. J. A.
DOBBS, S. M. *see* BOWES, S. G.
DOBBS, S. M. *see* O'NEILL, C. J. A.
DOHERTY, M. *see* JONES, A. C.
DOIG, J. K., MACFADYEN, R. J., LEES, K. R., SWEET, C. S. & REID, J. L. A dose-finding study of the angiotensin II antagonist, losartan (MK-954/DUP-53), in salt depleted subjects, 542P
DOLAN, R. *see* GRASBY, P.
DOLBEN, J., LUZIO, S., SMITH, H. & OWENS, D. R. Miglitol: a new alpha-glucosidase inhibitor decreases post-prandial glucose excursions, 225P
DOLLERY, C. T. *see* ARCHER, C. B.
DONNELLY, R. *see* MORRIS, A. D.
DONNELLY, R., ELLIOTT, H. L., MEREDITH, P. A., HOWIE, C. A. & REID, J. L. Dynamic and kinetic interactions of nifedipine and doxazosin in normal volunteers, 558P
DONZELLA, H. *see* SANTOS, S. R.
DOWELL, P. *see* CROME, P.
DRATWA, M. *see* SENNESAEL, J.
DREWE, J., BEGLINGER, C. & KISSEL, T. The absorption site of cyclosporin in the human gastrointestinal tract, 39
DUFFULL, S. B. *see* BEGG, E. J.
DUNDEE, J. W., MCMILLAN, C. M. & MAHDI, A. A. J. Anticipatory sickness in cancer chemotherapy, 243P
DUNDEE, J. W., MCMILLAN, C. M., YANG, J. & WRIGHT, P. M. C. Is ondansetron a less effective antiemetic against moderately emetic as compared with highly emetic chemotherapy? 200
DUSCI, L. J. *see* ILETT, K. F.
DUSCI, L. J. *see* LEBEDEVS, T. H.

ECKLAND, D. J. A., ENTWISLE, S. J., FOWLER, P. A., THOMAS, M., LETTIS, S., YORK, M. & FREEDMAN, P. S. The effects of sumatriptan, a 5-HT$_1$-like agonist, on pituitary adrenal function in healthy volunteers, 538P
EDELBROEK, P. M. *see* PIETERS, M. S. M.
EDWARDS, C. *see* KAMALI, K.
EDWARDS, G. & WARD, S. A. Methods in tropical pharmacology, 573
EDWARDS, R. J., GILROY, D. W., MURRAY, S., MURRAY, B. P. & BOOBIS, A. R. Disparate effects of 4-isopropyl-3,5-diethoxycarbonyl-1,4-dihydro-2,3,6-trimethylpyridine on CYP1A activities and apoprotein levels in the rat, 233P
EICHELBAUM, M. *see* MAST, V.
EICHELBAUM, M. *see* MEESE, C. O.
ELLIOTT, H. L. *see* DONNELLY, R.
ELLIOTT, H. L. *see* MACPHEE, G. J. A.
ELLIOTT, H. L. *see* WADE, J. R.
ELLIS, S. W. *see* BLANKSON, E. A.
ENGEL, T., SCHARLING, B., SKOVSTED, B. & HEINIG, J. H. Effects, side effects and plasma concentrations of terbutaline in adult asthmatics after inhaling from a dry powder inhaler device at different inhalation flows and volumes, 439
ENTWISLE, S. J. *see* ECKLAND, D. J. A.
ERIKSEN, U. H. *see* ANDREASEN, F.
ERKKOLA, R. *see* HEIKKILÄ, A.
ESCALONA, O. *see* BALDERSON, D. E.
EVANS, G. L. *see* MOORE, K.

FACCHINI, V. *see* PAGE, K. M.
FAJAC, I. *see* BRAUNSTEIN, G.
FAN CHUNG, K. *see* VENTRESCA, P. G.
FANG, J. & GORROD, J. W. Haloperidol, an MPTP-like neurotoxin? 230P
FARINOTTI, R. *see* BASCO, L. K.
FEE, J. P. H., COLLIER, P. S., LAUNCHBURY, A. P. & CLARKE, R. S. J. The influence of particle

size on the bioavailablility of inhaled temazepam, 641
FEEHALLY, M. J. *see* BEVAN, E. G.
FEELY, J. *see* MCCORMACK, P.
FEELY, J. *see* O'NEILL, D. O.
FEELY, J., O'BRYNE, S., CULLEN, M. & COOKE, T. Lipoprotein (a) in hypertensive diabetics and the effect of treatment, 562P
FEELY, M. *see* NEWTON-SMITH, F. A. O.
FENWICK, S. *see* MILLSON, D.
FERNANDES, M. H. *see* SOARES-DA SILVA, P.
FERNER, R. E. Hazards, risks and reality, 125
FINDLAY, J. G. *see* BEVAN, E. G.
FISCHER, C. *see* MAST, V.
FITSCHA, P. *see* SINZINGER, H.
FÖLSCH, U. R. *see* LÖSER, C. H. R.
FONSECA, V. *see* GILL, J.
FORD, G. A., HOFFMAN, B. B., VESTAL, R. E. & BLASCHKE, T. F. Age-related changes in adenosine and β-adrenoceptor responsiveness of vascular smooth muscle in man, 83
FORREST, A. R. W. Book review: Caffeine and health by Jack E. James, 209
FORSTER, J. K. *see* MACONOCHIE, J. G.
FORSTER, P. L. *see* RAPEPORT, W. G.
FORT, S. *see* JOHN, D. N.
FORT, S., JOHN, D. N., LUSCOMBE, D. K. & LEWIS, M. J. Sublingual verapamil is effective in the control of fast atrial flutter and fibrillation, 531P
FOSTER, R. W. & JUBBER, A. S. Bronchodilator effectiveness of oral MKS 492 assessed in normal human subjects, 239P
FOWLER, P. A. *see* ECKLAND, D. J. A.
FOWLER, P. A. *see* SWEETLAND, J.
FRACKOWIAK, R. *see* GRASBY, P.
FRANDSEN, H. *see* KELBÆK, H.
FRANDSEN, N. E. *see* HALLAS, J.
FREEDMAN, P. S. *see* ECKLAND, D. J. A.
FREEMAN, E. W., WEINSTOCK, L., RICKELS, K., SONDHEIMER, S. J. & COUTIFARIS, C. A placebo-controlled study of the effects of oral progesterone on performance and mood, 293
FREETH, C. J. *see* HORTON, R. C.
FRISK, M. *see* CROWE MCCANN, C.
FRISTON, K. *see* GRASBY, P.
FRITH, C. *see* GRASBY, P.
FROLUND, F. *see* HALLAS, J.
FROSSARD, N. *see* BRAUSTEIN, G.
FRÖLICH, M. *see* PIJL, H.
FUHRMANN, G. *see* HALABI, A.
FULLER, R. *see* BRAIN, S. D.
FULLERTON, M. *see* SHEN, A.
FUNCK-BRETANO, C. *see* THIOLLET, M.
GALLICANO, K. *see* SAHAI, J.
GANESH, S. *see* BAAK, L. C.
GARBER, G. *see* SAHAI, J.
GARRIDO, M. C. *see* NG, L. L.
GENISSEL, P. *see* SENNESAEL, J.
GEORGE, C. F. *see* ASHAN, C. H.
GILBURT, S. J. A., SUTTON, J. A. & HINDMARCH, I. The pharmacodynamics of brofaromine, alone and in combination with alcohol, in young healthy volunteers, 245P
GILL, J., FONSECA, V., DANDONA, P. & JEREMY, J. Y. Lisinopril and nifedipine administration inhibits the *ex vivo* uptake of [$^{45}Ca^{2+}$] by platelets from hypertensive diabetic patients, 161
GILLOTIN, C. *see* BASCO, L. K.
GILROY, D. W. *see* EDWARDS, R. J.
GIMENEZ, F. *see* BASCO, L. K.
GLOVER, D. R., NORRIS, T., BRYSON, S., HANCOCK, A. & BLACK, I. Prospective comparative post-marketing surveillance of loratadine by general practice computer network, 567P
GOLDBERG, M. R. *see* BURGGRAAF, J.
GOLDBERG, M. R. *see* SWIFT, R. H.
GOLDFARB, B. *see* CROWE MCCANN, C.
GOODERHAM, N. J. *see* RICH, K. J.
GORKOV, V. A. *see* KUDRIAKOVA, T. B.
GORROD, J. W. *see* AISLAITNER, G.
GORROD, J. W. *see* FANG, J.
GORROD, J. W. *see* JAHANSHAHI, M.
GORROD, J. W. *see* PATTICHIS, K.
GRAHAM, B. R. *see* WALDEN, R. J.
GRAM, L. F. *see* HALLAS, T.
GRANG, J.-D. *see* THIOLLET, M.
GRASBY, P., FRISTON, K., BENCH, C., FRITH, C., COWEN, P., FRACKOWIAK, R. & DOLAN, R. The effect of the 5-HT1A partial agonist, busipirone, on regional cerebral blood flow in man, 555P
GREAVES, J. L., WILSON, C. G., BIRMINGHAM, A. T., RICHARDSON, M. C. & BENTLEY, P. H. Scintigraphic studies on the corneal residence of a New Ophthalmic Delivery System (NODS): rate of clearance of a soluble marker in relation to duration of pharmacological act, 603
GREENE, P. K. *see* MURRAY, M. D.
GRIFFITHS, E., PATEL, P., JOHNSTON, A. & ABRAMS, S. M. L. *Avena sativa* compound: a herbal sedative? 244P
GRIMBEEK, R. J. *see* SOMMERS, DE K.
GRIMES, S. *see* SCOTT, A. K.
GRODUM, E. *see* HALLAS, J.
GROOM, P. J., CAMPBELL, L. M., LOUGH, J. R. M., NELEMANS, I., CUTHILL, A. R., GRUNDY, P. F., NANKANI, J., NORTHFIELD, M., RICHARDSON, P. D. I., TIMERICK, S. J. B. & WATTS, D. A. The use of digital electronic sphygmomanometers to measure blood pressure, 560P
GROSSET, D. G. What have drugs to offer the patient with acute stroke? 467
GRÖTSCH, H. *see* MEYER, B. H.
GRUNDY, P. F. *see* GROOM, P. J.
GRUNFELD, J. P. *see* BEVAN, E. G.
GRUNBERGER, J. *see* SALETU, B.
GUILIANI, L. *see* ROMITI, P.
GUILLET, P. *see* CROME, P.
GULATI, R. *see* BRETT, M. A.
GUUL, S.-J. *see* ANDREASEN, F.
GUY, S. *see* THAM, T. C. K.
GUYENNE, T. T. *see* CHAUVEAU, D.
HACKETT, L. P. *see* ILETT, K. F.
HACKETT, L. P. *see* LEBEDEVS, T. H.
HÄCKI, W. *see* WILDER-SMITH, C. H.
HADDARA, W. M. *see* CAMPBELL, N. R. C.
HADDOCK, R. E. *see* BLOOMER, J. C.
HAGEN, C. *see* HALLAS, J.
HAGHFELT, T. *see* HALLAS, J.
HALABI, A. *see* HINRICHSEN, H.
HALABI, A., HINRICHSEN, H., FUHRMANN, G. & KIRCH, W. Pirenzepine counteracts the negative chronotropic effect of nizatidine, 528P
HALE, J. P. *see* LENNARD, L.
HALL, S. D. *see* KNADLER, M. P.
HALL, S. D. *see* MURRAY, M. D.
HALL, S. T. *see* MOORE, K.
HALL, S. T., VERPOOTEN, G. A., WRIGHT, T., BABER, N. S., PELLEGATTI, M. & DE BROE, M. E. Evaluation of the pharmacodynamics and pharmacokinetics of calcium antagonist lacidipine in patients with impaired renal function, 559P
HALLAS, J., GRAM, L. F., GRODUM, E., DAMSBO, M., BROSEN, K., HAGHFELT, T., HARVALD, B., BECK-NIELSEN, J., WORM, J., BIRGER JENSEN, K., DAVIDSEN, O., FRANDSEN, N. E., HAGEN, C., ANDERSEN, M., FROLUND, F., KROMANN-ANDERSEN, H. & SCHOU, J. Drug related admissions to medical wards: a population based survey, 61
HALTER, F. *see* WILDER-SMITH, C. H.
HAMILTON, B. A. *see* ADAIR, C. G.
HANCOCK, A. *see* GLOVER, D. R.
HARAMBURU, F. *see* TUBERT, P.
HARRISON, A. C., MAGGS, J. L., KITTERINGHAM, N. R. & PARK, B. K. Metabolism and antigenicity of amodiaquine in the rat, 212P

HARRON, D. W. G. *see* BALDERSON, D. E.
HARRON, D. W. G. *see* THAM, T. C. K.
HARRY, J. D. *see* MILLSON, D. S.
HARTHOORN-LASTHUIZEN, E. J. *see* KROON, C.
HARTLING, O. J. *see* ANDREASEN, F.
HARVALD, B. *see* HALLAS, J.
HARVEY, S. *see* BLANCHARD, J.
HASINOFF, B. B. *see* CAMPBELL, N. R. C.
HAWKESFORD, J. E. *see* SEYMOUR, R. A.
HAWKESWORTH, G. M. *see* ABERNETHY, L.
HAWKSWORTH, G. M. *see* MCCLAREN, J.
HAWKSWORTH, G. M. *see* NEWLANDS, A. J.
HAWLEY-FOSS, N. *see* SAHAI, J.
HAWORTH, S. *see* MILLSON, D. S.
HAYES, J. R. *see* BRENNAN, G. M.
HAYNES, W. G. *see* THOMSON, M.
HEALD, A. *see* SWIFT, R. H.
HEALEY, M. *see* BOWES, S. G.
HEIKKILÄ, A., PYYKKÖ, K., ERKKOLA, R. & IISALO, E. The pharmacokinetics of mecillinam and pivmecillinam in pregnant and non-pregnant women, 629
HEINIG, J. H. *see* ENGEL, T.
HENRY, J. A. *see* MINTON, N. A.
HEPBURN, D. *see* WINSHIP, K.
HILLER, A. *see* ARANKO, K.
HILSTED, J. *see* KELBÆK, H.
HINDMARCH, I. *see* GILBURT, S. J. A.
HINDMARCH, I. *see* KILMINSTER, S.
HINRICHSEN, H. *see* HALABI, A.
HINRICHSEN, H., HALABI, A. & KIRCH, W. The influence of roxatidine on haemodynamic parameters assessed by non-invasive techniques, 556P
HLA, K. K. *see* MINTON, N. A.
HOETZEL, L. *see* BRETT, M. A.
HOFFMAN, B. B. *see* FORD, G. A.
HOLDICH, T. *see* ROLAN, P. E.
HOLDICH, T. A. *see* PECK, R. W.
HOLDING, J. D., LINDUP, W. E., VAN LAER, C., VREEBURG, G. C. M., WILSON, J. A. & STELL, P. M. Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck, 75
HOLGATE, S. T. *see* RICHARDS, R.
HOLGATE, S. T. *see* SUMMERS, Q. A.
HOLLIS, F. J. *see* BRETT, M. A.
HONEYWELL, R. G. *see* SUMMERS, Q. A.
HONKAKOSKI, P., ARVELA, P., JUVONEN, R., LANG, M. A., KAIRALUOMA, M. & PELKONEN, O. Human and mouse liver coumarin 7-hydroxylases do not metabolize warfarin *in vitro*, 313
HOOKER, M. *see* WILLIAMS, P. E. O.
HORTON, R. C., NAGLE, R. E., BROWN, T. M., SHAHI, M., POWIS, S. H., FREETH, C. J. & VANDENBURG, M. J. An open study to assess the effect of nitrolingual spray on haemodynamic parameters in patients with congestive heart failure, 223P
HÖTZEL, L. *see* KÖSTER, F. E.
HOWE, J. L., BACK, D. J. & COLBERT, J. Extrahepatic metabolism of zidovudine, 190
HOWIE, C. A. *see* DONNELLY, R.
HOWIE, C. A. *see* MACPHEE, G. J. A.
HUGHES, D. M. *see* WADE, J. R.
HUMPHREY, M. J. & SMITH, D. A. Hepatic uptake is the main factor in the apparent slow absorption of amlodipine, 219P
HUMPHREY, M. J., MCGIBNEY, D. & STOPHER, D. A. Variability in oral bioavailability for UK-52,831, a dihydropyridine calcium antagonist, between the fed and fasted states, 236P
HUNDHAUSEN, H.-J. *see* BRODDE, O.-E.
HUSSAIN, F. *see* MORGAN, P.
HUTCHINSON, , P. J. A. *see* TRILL, A. S.
HVIDT, S. *see* ANDREASEN, F.

IESTRA, J. A. *see* PIJL, H.
IISALO, E. *see* HEIKKILÄ, A.
ILETT, K. F. *see* LEBEDEVS, T. H.
ILETT, K. F., LEBEDEVS, T. H., WOJNAR-HORTON, R. E., YAPP, P., ROBERTS, M. J., DUSCI, L. J. & HACKETT, L. P. The excretion of dothiepin and its primary metabolites in breast milk, 635
IMBIMBO, B. *see* SWIFT, R. H.
IND, P. W. *see* SPRING, J.
ISHIZAKI, T. *see* SETIABUDY, R.
IZRAELI, M. R. S. *see* ZIV, I.

JACKSON, S. H. D. *see* TRILL, A. S.
JAHANSHAHI, M., KAJBAF, M. & GORROD, J. W. Comparative study of the *in vitro* and *in vivo* metabolism of an antimuscarinic drug in the rabbit, 228P
JAILLON, P. *see* THIOLLET, M.
JAKOBI, P. *see* KRIVOY, N.
JANES, S. & TIPPINS, J. R. Endothelial-dependent relaxation in human saphenous vein: effects of storage and distension, 222P
JANSEN, J. B. M. J. *see* BAAK, L. C.
JENNEKENS-SCHINKEL, A. *see* PIETERS, M. S. M.
JENNINGS, G. *see* SHEN, A.
JENSEN, S. *see* BRIDGES, A.
JEREMY, J. Y. *see* GILL, J.
JERWOOD, D. *see* NEWTON-SMITH, F. A. O.
JESSUP, C. L. *see* MILLSON, D. S.
JOHN, D. N. *see* FORT, S.
JOHN, D. N., FORT, S., LEWIS, M. J. & LUSCOMBE, D. K. Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers, 623
JOHNSTON, A. *see* GRIFFITHS, E.
JOHNSTON, A. *see* WARRINGTON, S.
JOHNSTON, G. D. *see* BRENNAN, G. M.
JONES, A. C. & DOHERTY, M. The treatment of osteoarthritis, 357
JONES, B. C. *see* NEWLANDS, A. J.
JONES, G. D. *see* PAGE, K. M.
JONES, S. L. *see* BARROW, S. E.
JORGENSEN, J. T. *see* BRIDGES, A.
JUBBER, A. S. *see* FOSTER, R. W.
JUVONEN, R. *see* HONKAKOSKI, P.

KAHN, M. *see* NIGHAT
KAHR, O. *see* ANDREASEN, F.
KAIRALUOMA, M. *see* HONKAKOSKI, P.
KAJBAF, M. *see* JAHANSHAHI, M.
KAJBAF, M. *see* PATTICHIS, K.
KAJJALA, S. *see* SANTOS, S. R.
KALSO, E. *see* PYHIA, R.
KAMALI, F. Paracetamol conjugation in patients with non-insulin-dependent diabetes mellitus, 552P
KAMALI, F., EDWARDS, C. & RAWLINS, M. D. The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics, 309
KARA, M. *see* CAMPBELL, N. R. C.
KARVONEN, J. I. *see* NIEMINEN, M. M.
KAVANAGH, G. M. *see* ARCHER, C. B.
KELBÆK, H., FRANDSEN, H., HILSTED, J., CHRISTENSEN, N. J. & NIELSEN, S. L. Effects of α-adrenoceptor and of combined sympathetic and parasympathetic blockade on cardiac performance and vascular resistance, 473
KELLY, P. *see* SEYMOUR, R. A.
KELNAR, C. *see* BRIDGES, A.
KENNEDY, J. M., VAN RIJ, A. M. & PETTIGREW, R. A. Cardiovascular drug therapy in patients admitted to a general surgical unit, 557P
KHUROO, M. S., ZARGAR, S. A. & YATTOO, G. N. Efficacy of nifedipine therapy in patients with sphincter of Oddi dysfunction: a prospective, double-blind, randomized, placebo-controlled, cross over trial, 477
KILMINSTER, S. & HINDMARCH, I. Cognition and mood in elderly depressed patients treated with

either fluoxetine or amitriptyline, 245P
KING, D. J. & MANNION, M. F. Absence of acute tolerance to the effects of diazepam on saccadic eye movements, 549P
KINT, A. *see* MEYER, E.
KIRCH, W. *see* BAMMEL, A.
KIRCH, W. *see* HALABI, A.
KIRCH, W. *see* HINRICHSEN, H.
KIRKHAM, F. J. *see* WINSTANLEY, P. A.
KISSEL, T. *see* DREWE, J.
KITTERINGHAM, N. R. *see* HARRISON, A. C.
KITTERINGHAM, N. R. *see* PIRMOHAMED, M.
KIVIST, K. T. *see* NEUVONEN, P. J.
KLEINBLOESEM, C. H. *see* BOEIJINGA, J. K.
KNADLER, M. P., BRATER, D. C. & HALL, S. D. Stereoselective disposition of flurbiprofen in normal volunteers, 369
KNADLER, M. P., BRATER, D. C. & HALL, S. D. Stereoselective disposition of flurbiprofen in uraemic patients, 377
KONTESSIS, P. S. *see* BARROW, S. E.
KOPPESCHAAR, H. P. F. *see* PIJL, H.
KOSKINEN, M. O. *see* NIEMINEN, M. M.
KÖSTER, F. E., ALLEN, G. D., LANGLEY, P. F., PALM, M., HÖTZEL, L. & KUKOVETZ, W. R. Absorption metabolism and excretion of [^{14}C]-denbufylline in man after intravenous and oral administration, 236P
KRAAY, C. J. *see* BOEIJINGA, J. K.
KRAUL, H. *see* PELKONEN, O.
KRIVOY, N. VADASZ, A., STOLER, J., JAKOBI, P. & MAKLER, A. Letter to the Editors: The *in vitro* effect of exogenous digoxin on normal human spermatozoa progressive motility, 203
KROMANN-ANDERSEN, H. *see* HALLAS, J.
KROON, C., TEN HOVE, W. R., DE BOER, A., KROON, J. M., VAN DER POL, J. M. J., HARTHOORN-LASTHUIZEN, E. J., SCHOEMAKER, H. C., VAN DER MEER, F. J. M. & COHEN, A. F. Highly variable anticoagulant response after subcutaneous administration of high dose (12500 i.u.) heparin in patients and healthy volunteers, 541P
KROON, J. M. *see* KROON, C.
KROON, J. M. *see* VAN SEVENINCK, A. L.
KUDRIAKOVA, T. B., SIROTA, L. A., ROZOVA, G. I. & GORKOV, V. A. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites, 611
KUKOVETZ, W. R. *see* KOSTER, F. E.
KUSAKA, M. *see* SETIABUDY, R.

LAMBERT, W. *see* MEYER, E.
LAMERS, C. B. H. W. *see* BAAK, L. C.
LAND, G. *see* YUEN, A. W. C.
LANG, M. A. *see* HONKAKOSKI, P.
LANGLEY, P. F. *see* KÖSTER, F. E.
LANSER, J. B. K. *see* PIETERS, M. S. M.
LARKIN, J. G., MCKEE, P. J. W. & BRODIE, M. J. Rapid tolerance to acute psychomotor impairment with carbamazepine in epileptic patients, 111
LAUNCHBURY, A. P. *see* FEE, J. P. H.
LAWSON, D. H. *see* WINSHIP, K.
LE BRAS, J. *see* BASCO, L. K.
LEBEDEVS, T. H. *see* ILETT, K. F.
LEBEDEVS, T. H., WOJNAR-HORTON, R. E., YAPP, P., ROBERTS, M. J., DUSCI, L. J., HACKETT, L. P. & ILETT, K. F. Letter to the Editor: Excretion of temazepam in breast milk, 204
LEE, S. C. & RENWICK, A. G. The enzymatic reduction of sulphoxide-containing drugs by *Escherichia coli*, 212P
LEENEN, F. H. H. *see* LEVINE, M. A. H.
LEES, K. R. *see* DOIG, J. K.
LENNARD, L., HALE, J. P. & LILLEYMAN, J. S. Modulation of 6-mercaptopurine active metabolite formation in childhood leukaemia, 552P
LENNARD, M. S. *see* BARHAM, H. M.
LENNARD, M. S. *see* BLANKSON, E. A.
LENNARD, M. S. *see* BLOOMER, J. C.
LENNOX, S. V. *see* MURRAY, B. P.
LEONE, C. R. *see* SANTOS, S. R.
LEONHARDT, A., SCHWEER, H., WOLF, D. & SEYBERTH, H. W. Formation of biologically active 13,14-dihydroprostaglandin E_1 during intravenous infusion of prostaglandin E_1 in newborns with ductus arteriosus-dependent congenital heart disease, 323
LETTIS, S. *see* ECKLAND, D. J. A.
LETTIS, S. *see* MILLSON, D.
LETTIS, S. *see* SWEETLAND, J.
LEUNG, N. K.-C. *see* BRADSHAW, C. M.
LEUNG, N. K.-C., BRADSHAW, C. M. & SZABADI, E. Effects of high ambient temperature on kinetics of the pupillary light reflex in healthy volunteers, 458
LEVINE, M. A. H. & LEENEN, F. H. H. Role of vagal activity in the cardiovascular responses to phenylephrine in man, 333
LEWIS, I. *see* RICH, K. J.
LEWIS, M. J. *see* FORT, S.
LEWIS, M. J. *see* JOHN, D. N.
LEWIS, Y. *see* WARRINGTON, S.
LILLEYMAN, J. S. *see* LENNARD, L.
LINDUP, W. E. *see* HOLDING, J. D.
LINZMAYER, L. *see* SALETU, B.
LIPWORTH, B. J. & MCDEVITT, D. G. Inhaled β_2-adrenoceptor agonists in asthma: help or hindrance? 129
LIPWORTH, B. J. *see* WHEELDON, N. M.
LOCKE, C. S. *see* ORCHARD, M. A.
LÖSER, C. H. R., CLEFFMANN, U., ALVES, F. & FÖLSCH, U. R. Effects of eflornithine (α-difluoro methyl-ornithine) on polyamine metabolism and camostate (Foy 305)-induced pancreatic growth in rats, 535P
LOTTER, C. S. *see* MEYER, B. H.
LOUGH, J. R. M. *see* GROOM, P. J.
LUBEL, D. *see* BOWES, S. G.
LUSCOMBE, D. K. *see* FORT, S.
LUSCOMBE, D. K. *see* JOHN, D. N.
LUU, T. N., DASHWOOD, M. R., MUDDLE, J. R., CHESTER, A. H. & YACOUB, M. H. Effect of vasoactive intestinal peptide and localization of [^{125}I]-VIP binding sites in human blood vessels used for coronary artery bypass grafting, 222P
LUUS, H. G. *see* MEYER, B. H.
LUZIO, S., *see* DOLBEN, J.
LYNN, K. L. *see* ROBSON, R. A.

MACFADYEN, R. J. *see* DOIG, J. K.
MACKAY, J., MACKIE, A. E., PALMER, J. L., MOULT, A. & BABER, N. S. Investigations into the mechanism for the improved oral systemic bioavailability of cefuroxime from cefuroxime axetil when taken after food, 226P
MACKIE, A. E. *see* MACKAY, J.
MACLEOD, R. *see* BACK, D. J.
MACONOCHIE, J. G. & FORSTER, J. K. Dose-response study with high-dose inhaled salmeterol in healthy subjects, 342
MACPHEE, G. J. A., HOWIE, C. A., ELLIOTT, H. L. & REID, J. L. A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects, 261
MADDEN, B. *see* CHESTER, M. R.
MAGGS, J. L. *see* ABEL, S. M.
MAGGS, J. L. *see* HARRISON, A. C.
MAGGS, J. L. *see* MORGAN, P.
MAGNI, G. *see* SALETU, B.
MAHDI, A. A. J. *see* DUNDEE, J. W.
MAK, M. C. *see* TOMLINSON, B.
MAKLER, A. *see* KRIVOY, N.
MALAQUIN, F. *see* BRAUNSTEIN, G.
MALING, T. J. & PUVI-RAJASINGHAM, R. The blood

pressure lowering effect of midazolam, 532P
MANATUNGA, A. K. *see* MURRAY, M. D.
MANNION, M. F. *see* KING, D. J.
MANT, T. *see* ROSE, J.
MANT, T. G. *see* SWIFT, R. H.
MARRIOTT, J. F., ASQUITH, P. A. & SHORROCK, C. J. An investigation of the use of proprietary medicines by patients experiencing a peptic ulcer bleed, 240P
MARSH, K. *see* WINSTANLEY, P. A.
MARSHMAN, G. *see* ARCHER, C. B.
MAST, V., FISCHER, C., MIKUS, G. & EICHELBAUM, M. Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers, 51
MATTILLA, M. E. *see* MATTILA, M. J.
MATTILA, M. J. Ebastine administered subacutely does not impair human performance or enhance diazepam effects, 244P
MATTILA, M. J., ARANKO, K. & MATTILA, M. E. Effects of diazepam on digit substitution: a comparison of computerized *vs* paper and pencil tests, 570P
MBERU, E. *see* WINSTANLEY, P. A.
MCCAFFREY, P. M. *see* THAM, T. C. K.
MCCALLION, O. *see* ADAIR, C. G.
MCCANN, J. P. *see* ADAIR, C. G.
MCCLAREN, J., WHITING, P. H. & HAWKSWORTH, G. M. Inhibition of glucose transport by aminoglycosides in isolated suspensions of human proximal tubular cells, 217P
MCCORMACK, P. O'REILLY, E., WALSH, J. B., COAKLEY, D. & FEELY, J. A prospective study of adverse drug interactions, 539P
MCDADE, G. *see* THEOPHILOPOULOS, N.
MCDEVITT, D. G. *see* LIPWORTH, B. J.
MCDEVITT, D. G. *see* WHEELDON, N. M.
MCDOWELL, I. *see* NUGENT, A. M.
MCDOWELL, J. *see* BRIDGES, A.
MCELNAY, J. C. *see* ADAIR, C. G.
MCGILVERAY, I. *see* SAHAI, J.
MCINNES, G. T. *see* BEVAN, E. G.
MCKAY, D. W. *see* CAMPBELL, N. R. C.
MCKEE, P. J. W. *see* LARKIN, J. G.
MCKEE, P. W. J., BLACKLAW, J., THOMPSON, G. G. & BRODIE, M. J. Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage? 548P
MCMILLAN, C. M. *see* DUNDEE, J. W.
MCPARLAND, G. *see* SILKE, B.
MCVEIGH, G. E. *see* BRENNAN, G. M.
MEESE, C. O., WISSER, H. & EICHELBAUM, M. The metabolic fate of [^{14}C]-carbocysteine in humans, 536P
MEHTA, R. *see* BOWES, S. G.
MEINDERS, A. E. *see* PIJL, H.
MEINEKE, I. *see* DE MEY, C.
MEIRE, H. *see* ROLAN, P. E.
MELAC, M. *see* BRAUNSTEIN, G.
MENAHEM, S. *see* ZIV, I.
MÉNARD, J. *see* CHAUVEAU, D.
MERCER, A. J. *see* ROLAN, P. E.
MEREDITH, P. A. *see* DONNELLY, R.
MEREDITH, P. A. *see* WADE, J. R.
MERKI, H. S. *see* WILDER-SMITH, C. H.
METSÄ–KETELÄ, T. J. *see* NIEMINEN, M. M.
MEYER, B. H. *see* BEVAN, E. G.
MEYER, B. H., LUUS, H. G., MULLER, F. O., BADENHORST, P. N., LOTTER, M. G., RÖTHIG, H. J., GRÖTSCH, H. & ROSENKRANZ, B. Recombinant hirudin, a new anticoagulant, has no effect on faecal blood loss, 562
MEYER, E., LAMBERT, W., DE LEENHEER, A., DE BERSAQUES, J. & KINT, A. The distribution of cis- and trans-acitretin in human epidermis, 187
MEYER, E. C. *see* SOMMERS, DE K.
MEYER, P. *see* CROWE MCCANN, C.
MICHEL, M. C. *see* BRODDE, O.-E.
MIDAVAINE, M. *see* THIOLLET, M.
MIKUS, G. *see* MAST, V.
MILLEDGE, J. S. *see* O'NEILL, C. J. A.
MILLSON, D., SOHAIL, S., LETTIS, S. & FENWICK, S. Duration of inhibition of the flare response to intradermal 5-hydroxytryptamine in man by GR68755, a novel specific 5-HT$_3$ receptor antagonist, 546P
MILLSON, D. S. *see* PRESTON, G. C.
MILLSON, D. S. *see* VENTRESCA, G. P.
MILLSON, D. S., JESSUP, C. L., SWAISLAND, A., HAWORTH, S., RUSHTON, A. & HARRY, J. D. The effects of a selective 5-HT$_2$ receptor antagonist (ICI 170,809) on platelet aggregation and pupillary responses in healthy volunteers, 281
MINTON, N. A., HLA, K. K., CHILTON, J. E. & HENRY, J. A. Ipecacuanha-induced emesis: a potential human model for testing the anti-emetic activity of 5-HT$_3$-receptor antagonists, 221P
MISSO, N. L. A. *see* TAYLOR, M. L.
MISTRY, R. *see* CAHILL, M.
MITCHELL, R. H. *see* BALDERSON, D. E.
MOILANEN, E. K. *see* NIEMINEN, M. M.
MONCRIEFF, J. *see* SOMMERS, DE K.
MOORE, K., HALL, S. T., PALMER, J. L., EVANS, G. L., STEWART-LONG, P., BABER, N. S. & WILLIAMS, R. A study to assess the pharmacodynamics and pharmacokinetics of calcium antagonist lacidpine in patients with impaired hepatic function, 560P
MORGAN, P., MAGGS, J. L., HUSSAIN, F., PAGE, P. C. B. & PARK, B. K. The metabolism of 2-fluoro-17α-ethinyl-17-β-oestradiol in the rat, 231P
MORGAN, W. J. *see* BLANCHARD, J.
MORRIS, A. D., DONNELLY, R., CONNELL, J. M. C. & REID, J. L. The effects of lacidipine on insulin sensitivity: a placebo controlled study using the euglycaemia clamp, 537P
MORRIS, J. S. *see* ARNOLD, J. D.
MORRISON, P. *see* ROSE, J.
MORRISON, P. J. *see* SWIFT, R. H.
MOULT, A. *see* MACKAY, J.
MUDDLE, J. R. *see* DASHWOOD, M. R.
MUDDLE, J. R. *see* LUU, T. N.
MUIRHEAD, G. J. *see* WILLIAMS, P. E. O.
MULLER, F. O. *see* MEYER, B. H.
MURDOCH, D. L. *see* BEVAN, E. G.
MURRAY, B. P. *see* EDWARDS, R. J.
MURRAY, B. P. *see* RICH, K. J.
MURRAY, B. P., LENNOX, S. V., MURRAY, S. & BOOBIS, A. R. Potent *in vitro* inhibition of human CYP1A2 by pharmacologically diverse agents, 233P
MURRAY, G. D. *see* BEVAN, E. G.
MURRAY, M. D., GREENE, P. K., BRATER, D. C., MANATUNGA, A. K. & HALL, S. D. Effects of flurbiprofen on renal function in patients with moderate renal insufficiency, 385
MURRAY, S. *see* EDWARDS, R. J.
MURRAY, S. *see* MURRAY, B. P.
MWANGI, I. N. *see* WINSTANLEY, P. A.
MÄEPÄÄ, J. *see* PELKONEN, O.

NAGLE, R. E. *see* HORTON, R. C.
NANKANI, J. *see* GROOM, P. J.
NEELY, D. *see* NUGENT, A. M.
NELEMANS, I. *see* GROOM, P. J.
NEUVONEN, P. J. & KIVIST, K. T. Milk and yoghurt do not impair the absorption of ofloxacin, 346
NEVILL, C. *see* WINSTANLEY, P. A.
NEWBY, S. *see* ABEL, S. M.
NEWLANDS, A. J., BURKE, M. D., WEAVER, R., SMITH, D. A., JONES, B. C. & HAWKSWORTH, G. M. Aldrin and felodipine metabolism as indicators of

cytochrome P450 IIIA activity in human liver microsomes, 226P
NEWTON, C. R. J. C. *see* WINSTANLEY, P. A.
NEWTON-SMITH, F. A. O., DAWSON, P. H., COOKE, J., FEELY, M., BOOTH, T. G., JERWOOD, D. & CALVERT, R. T. The influence of the academic representative on prescribing by general practitioners, 69
NG, H. W. K., WALLEY, T. J., TSAO, Y. & BRECKENRIDGE, A. M. Lack of interaction of flosequinan and xamoterol in central and peripheral haemodynamics at supine rest in normal subjects, 557P
NG, K. *see* SCOTT, A. K.
NG, L. L., GARRIDO, M. C., DAVIES, J. E., BROCHWICZ-LEWINSKI, M. J. & TAN, L. B. Intracellular free magnesium in lymphocytes from patients with congestive heart failure treated with loop diuretics with and without amiloride, 329
NICHOL, G. M. *see* VENTRESCA, P. G.
NICHOLLS, D. P. *see* ADAIR, C. G.
NICHOLLS, D. P. *see* NUGENT, A. M.
NICHOLLS, D. P. *see* O'KANE, M. J.
NICHOLLS, M. G. *see* CHAN, J. C. N.
NICHOLSON, E. *see* SEYMOUR, R. A.
NICHOLSON, P. W. *see* O'NEILL, C. J. A.
NIELSEN, L. P. *see* ANDREASEN, F.
NIELSEN, S. L. *see* KELBÆK, H.
NIEMINEN, M. M., MOILANEN, E. K., KOSKINEN, M. O., KARVONEN, J. I., TUOMISTO, L., METSÄ–KETELÄ, T. J. & VAPAATALO, H. Inhaled budesonide fails to inhibit the PAF-induced increase in plasma leukotriene B_4 in man, 645
NIGHAT, KAHN, M. & SAEED, S. A. Platelet hyperactivity to arachidonic acid in normal and pregnancy-induced hypertension, 224P
NOKHODIAN, A. *see* BAMMEL, A.
NORRIS, T. *see* GLOVER, D. R.
NORTHFIELD, M. *see* GROOM, P. J.
NUGENT, A. M., NEELY, D., YOUNG, I., MCDOWELL, I., O'KANE, M. & NICHOLLS, D. P. Simvastatin and stress responses, 538P
NUGENT, A.-M., RILEY, M., PRASANNA, K., STANFORD, C. F. & NICHOLLS, D. P. Xamoterol in severe heart failure, 543P
NUTT, J. *see* WALDEN, R. J.

O'BYRNE, S. *see* FEELY, J.
O'GRADY, J. *see* SINZINGER, H.
O'KANE, M. *see* NUGENT, A. M.
O'KANE, M. J., TRINICK, T. R., TYNAN, M. B., TRIMBLE, E. R. & NICHOLLS, D. P. A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia, 451
O'KEEFE, B. *see* BALDERSON, D. E.
O'NEILL, C. J. A. *see* BOWES, S. G.
O'NEILL, C. J. A., CHARLETT, A., DOBBS, R. J., DESHMUKH, A. A., BOWES, S. G., WELLER, C., NICHOLSON, P. W., MILLEDGE, J. S. & DOBBS, S. M. Effect of captopril on functional, physiological and biochemical outcome criteria in aged heart failure patients, 167
O'NEILL, D. O., ROWAN, M., WALSH, J. B., COAKLEY, D. & FEELY, J. L-acetyl-carnitine and the P300 in senile dementia of theAlzheimer type, 220P
O'REILLY, E. *see* MCCORMACK, P.
OLKKOLA, K. T. *see* ARANKO, K.
OLKKOLA, K. T. *see* PYHIA, R.
OLSSON, G. L. *see* QUIDING, H.
OMOSAKO, C. E. *see* SANTOS, S. R.
ONKENHOUT, P. *see* PIJL, H.
ORCHARD, M. A., WARD, C., LOCKE, C. S. & RINGHAM, G. L. Investigation of oral Abbott-73001 (Takeda AA-2414) on platelet function in normal volunteers, 541P
ORMESHER, S. *see* BACK, D. J.
OWENS, C. W. I. *see* WALDEN, R. J.
OWENS, D. R. *see* DOLBEN, J.

PACIFICI, G. M. *see* ROMITI, P.
PACIFICI, G. M. *see* VIANI, A.
PAGE, K. M., JONES, G. D., PAGE, M. R., WILSHER, N. E. & FACCHINI, V. Species differences in the plasma protein binding and blood hydrolysis of RP 61060, a novel HMG CoA reductase inhibitor, 553P
PAGE, M. R. *see* PAGE, K. M.
PAGE, P. C. B. *see* MORGAN, P.
PALM, M. *see* KÖSTER, F. E.
PALMER, C. N. A., COATES, P. J., DAVIES, S., SHEPHARD, E. A. & PHILLIPS, I. R. Human cytochrome P-450 genes: developmental and tissue specific regulation and inter-individual variation in expression, 218P
PALMER, J. L. *see* MACKAY, J.
PALMER, J. L. *see* MOORE, K.
PARK, B. K. *see* ABEL, S. M.
PARK, B. K. *see* HARRISON, A. C.
PARK, B. K. *see* MORGAN, P.
PARK, B. K. *see* PIRMOHAMED, M.
PARK, B. K. *see* TINGLE, M. D.
PASVOL, G. *see* WINSTANLEY, P. A.
PATEL, P. *see* GRIFFITHS, E.
PATERSON, S. Pharmacokinetics of dipipanone after a single oral dose, 449
PATTICHIS, K., KAJBAF, M. & GORROD, J. W. Intermediates involved in the *in vitro* metabolism of mifentidine, 229P
PAULY, N. *see* BEVAN, E. G.
PECK, A. E. *see* YUEN, A. W. C.
PECK, R. W., POSNER, J., WEATHERLEY, B., HOLDICH, T. A. & WHITEMAN, P. D. Tolerability and pharmacokinetics of 882C, a novel nucleoside analogue, in healthy male volunteers, 568P
PELKONEN, O. *see* HONKAKOSKI, P.
PELKONEN, O., RAUTIO, A., KRAUL, H., MÄENPÄÄ, J. & SIGUSCH, H. Coumarin 7-hydroxylation *in vivo* in mouse and man, 214
PELLEGATTI, M. *see* HALL, S. T.
PÉRÉ, J.-C. *see* TUBERT, P.
PEREIRA, M. D. *see* SANTOS, S. R.
PESHU, N. *see* WINSTANLEY, P. A.
PESTANA, M. *see* SOARES-DA SILVA, P.
PETERS, A. C. B. *see* PIETERS, M. S. M.
PETERS, W. H. M. *see* WEBBER, I. R.
PETTIGREW, R. A. *see* KENNEDY, J. M.
PFEIFFER, P. *see* BRETT, M. A.
PHILLIPS, I. R. *see* PALMER, C. N. A.
PIETERS, M. S. M. *see* VAN STEVENINCK, A. L.
PIETERS, M. S. M., JENNEKENS-SCHINKEL, A., LANSER, J. B. K., BROUWER, O. F., STIJNEN, T. H., EDELBROEK, P. M. & PETERS, A. C. B. Carbamazepine controlled release compared with conventional carbamazepine: a controlled study of attention and vigilance in epileptic children, 547P
PIETERS, M. S. M., JENNEKENS-SCHINKEL, A., SCHOEMAKER, H. C. & COHEN, A. F. Self-selection for personality variables among healthy volunteers, 101
PIJL, H., COHEN, A. F., IESTRA, J. A., SCHOEMAKER, H. C., KOPPESCHAAR, H. P. F., FRLICH, M., ONKENHOUT, P. & MEINDERS, A. E. 5-HT-mediated control of macronutrient selection in normal weight human subjects, 536P
PILGRIM, A. J. *see* SCOTT, A. K.
PIPER, P. J. *see* SAMPSON, A. P.
PIRMOHAMED, M., KITTERINGHAM, N. R., BRECKENRIDGE, A. M. & PARK, B. K. Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity, 183
PIRMOHAMED, M., TEMPLETON, E., BRECKENRIDGE, A. M. & PARK, B. K. Bioactivation of lofepramine to a cytotoxic metabolite by

human and mouse liver microsomes, 232P
PORRAS, A. *see* BURGGRAAF, J.
POSNER, J. *see* PECK, R. W.
POSNER, J. *see* ROLAN, P. E.
POWIS, S. H. *see* HORTON, R. C.
PÖYHIA, R., SEPPÄLÄ, T., OLKKOLA, K. T. & KALSO, E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects, 617
PRASANNA, K. *see* NUGENT, A.-M.
PRESTON, G. C., MILLSON, D. S., CEUPPENS, P. R. & WARBURTON, D. M. Effects of the 5-HT_3 receptor antagonist GR68755 on a scopolamine induced cognitive deficit in healthy subjects, 546P
PRICHARD, B. N. C. *see* WALDEN, R. J.
PUVI-RAJASINGHAM, R. *see* MALING, T. J.
PYYKKÖ, K. *see* HEIKKILÄ, A.

QUERA-SALVA, M. A. *see* CROWE MCCANN, C.
QUIDING, H., OLSSON, G. L., BOREUS, L. O. & BONDESSON, U. Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration, 45

RANE, A. & ASK, B. A conspicuous down-regulating effect of morphine on essential steroid hydroxylation reaction and certain drug *N*-demethylations, 215P
RAPEPORT, W. G., DEWLAND, P. M., MUIRHEAD, D. C. & FORSTER, P. L. Lack of an interaction between azithromycin and carbamazepine, 557P
RAUSCHA, F. *see* SINZINGER, H.
RAUTIO, A. *see* PELKONEN, O.
RAWLINS, M. D. Roles and responsibilities of clinical pharmacology: government and governmental bodies, 365
RAWLINS, M. D. *see* KAMALI, F.
RAWLINS, M. D. *see* WALLER, P. C.
REID, J. L. *see* DOIG, J. K.
REID, J. L. *see* DONNELLY, R.
REID, J. L. *see* MACPHEE, G. J. A.
REID, J. L. *see* MORRIS, A. D.
RENWICK, A. G. *see* ASHAN, C. H.
RENWICK, A. G. *see* BUSS, N. E.
RENWICK, A. G. *see* LEE, S. C.
RENWICK, A. G. *see* RICHARDS, R.
RENWICK, A. G. *see* SUMMERS, Q. A.
RESPLANDY, G. *see* SENNESAEL, J.
RESPLANDY, G. *see* THIOLLET, M.
RESTORICK, J. *see* ROSE, J.
RHODES, J. *see* ARNOLD, J. D.
RICH, K. J., MURRAY, B. P., GOODERHAM, N. J., LEWIS, I., DAVIES, D. S. & BOOBIS, A. R. CYP1A2 is responsible for the hepatic microsomal metabolism of MeIQx to N-hydroxy MeIQx in man, 213P
RICHARDS, R., SIMPSON, S., RENWICK, A. G. & HOLGATE, S. T. Inhaled histamine increases the rate of absorption of sodium cromoglycate from the lung, 337
RICHARDSON, M. C. *see* GREAVES, J. L.
RICHARDSON, P. D. I. *see* GROOM, P. J.
RICKELS, K. *see* FREEMAN, E. W.
RIDDELL, J. G. *see* THAM, T. C. K.
RIDOUT, *see* ROLAN, P. E.
RIJNKELS, J. M. *see* VAN STEVENINCK, A. L.
RILEY, M. *see* NUGENT, A.-M.
RINGHAM, G. L. *see* ORCHARD, M. A.
RITTER, J. M. *see* BARROW, S. E.
RIZZO, G. *see* VIANI, A.
ROBERTS, M. J. *see* ILETT, K. F.
ROBERTS, M. J. *see* LEBEDEVS, T. H.
ROBSON, R. A., BRIDGMAN, P. G., WELLS, J. E., BAILEY, R. R. & LYNN, K. L. The effect of celiprolol on glomerular filtration rate and renal blood flow in patients with chronic renal impairment and healthy volunteers, 454
RODEN, D. M. *see* BIRGERSDOTTER, U. M.
ROGERS, K. *see* BLANKSON, E. A.
ROLAN, P. E., MERCER, A. J. WEATHERLEY, B. C., HOLDICH, T., RIDOUT, G., MEIRE, H. & POSNER, J. Investigation of the factors responsible for a food-induced increase in absorption of a novel antiprotozoal drug 566C80, 534P
ROMITI, P., GUILIANI, L. & PACIFICI, G. M. Interindividual variability in the *N*-sulphation of desipramine in human liver and platelets, 17
ROSE, J., MANT, T., MORRISON, P., RESTORICK, J. & ACTON, G. Safety, tolerability, renal effects and pharmacokinetics in man of single doses of FK453, a novel adenosine A_1-receptor antagonist, 238P
ROSENKRANZ, B. *see* MEYER, B. H.
RÖTHIG, H. J. *see* MEYER, B. H.
ROUSSEAU, F. S. *see* WILLIAMS, P. E. O.
ROWAN, M. *see* O'NEILL, D. O.
ROZOVA, G. I. *see* KUDRIAKOVA, T. B.
RUDLAND, P. S. *see* WILD, M. J.
RUSHTON, A. *see* MILLSON, D. S.

SAARNIVAARA, L. *see* ARANKO, K.
SAEED, S. A. *see* NIGHAT
SAHAI, J., GALLICANO, K., GARBER, G., MCGILVERAY, I., HAWLEY-FOSS, N., TURGEON, N. & CAMERON, D. W. The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients, 658
SALETU, B., GRÜNBERGER, J., ANDERER, P., LINZMAYER, L., SEMLITSCH, H. V. & MAGNI, G. Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology, 589
SAMPSON, A. P., THOMAS, R. U., COSTELLO, J. F. & PIPER, P. J. Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects, 423
SANSOM, J. E. *see* ARCHER, C. B.
SANTOS, S. R., TROSTER, E. J., LEONE, C. R., OMOSAKO, C. E., PEREIRA, M. D., DONZELLA, H., BERTOLINE, M. A., DELLA PASCHOA, O. E., ZUGAIB, M., KAJJALA, S. & SCHVARTSMAN, S. Transfer of pindolol across the placenta in hypertensive pregnant women undergoing long term therapy and its consequence to the newborn, 561P
SANTOS, S. R. C. J. *see* BAMMEL, A.
SCHALIJ, M. J. *see* BURGGRAAF, J.
SCHARLING, B. *see* ENGEL, T.
SCHOEMAKER, H. C. *see* KROON, C.
SCHOEMAKER, H. C. *see* PIETERS, M. S. M.
SCHOEMAKER, H. C. *see* PIJL, H.
SCHOEMAKER, H. C. *see* VAN GRIENSVEN, J. M. T.
SCHOEMAKER, H. C. *see* VAN STEVENINCK, A. L.
SCHOEMAKER, R. C. *see* COHEN, A.
SCHOU, J. *see* HALLAS, J.
SCHVARTSMAN, S. *see* SANTOS, S. R.
SCHWEER, H. *see* LEONHARDT, A.
SCIBBERAS, D. G. *see* SWIFT, R. H.
SCIBERRAS, D. G., BRAIN, S. D. & WILLIAMS, T. J. The inflammatory effects of CGRP and substance P in human skin, 247P
SCOTT, A. K., GRIMES, S., NG, K., CRITCHLEY, M., BRECKENRIDGE, A. M., THOMSON, C. & PILGRIM, A. J. Sumatriptan and cerebral perfusion in healthy volunteers, 401
SCOTT, G. M. S. *see* VENNING, G. R.
SCOTT, M. E. *see* SILKE, B.
SCOTT, M. G. *see* ADAIR, C. G.
SEIBERT-GRAF, M. *see* VAN GRIENSVEN, J. M. T.
SEMLITSCH, H. V. *see* SALETU, B.
SENNESAEL, J., ALI, A., SWENY, P., VANDENBURG, M., SLOVIC, D., DRATWA, M., RESPLANDY, G., GENISSEL, P. & DESCHE, P. The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme

activity in hypertensive patients with chronic renal failure, 93
SEPPÄLÄ, T. *see* PÖYHIA, R.
SERINI, D. *see* WILLIAMS, P. E. O.
SETIABUDY, R., CHIBA, K., KUSAKA, M. & ISHIZAKI, T. Caution in the use of a 100 mg dose of racemic mephenytoin for phenotyping Southeastern Oriental subjects, 665
SEYBERTH, H. W. *see* LEONHARDT, A.
SEYMOUR, R. A., WELDON, M., KELLY, P., NICHOLSON, E. & HAWKESFORD, J. E. An evaluation of buffered aspirin and aspirin tablets in post-operative pain after third molar surgery, 395
SHAHI, M. *see* HORTON, R. C.
SHANKS, R. G. *see* THAM, T. C. K.
SHEIK, V. *see* SILKE, B.
SHEN, A., CHIN, J., FULLERTON, M., JENNINGS, G. & DART, A. Increases in plasma β-endorphin concentrations during exercise do not contribute to increases in heart rate following autonomic blockade in man, 89
SHEPHARD, E. A. *see* PALMER, C. N. A.
SHORROCK, C. J. *see* MARRIOTT, J. F.
SIGUSCH, H. *see* PELKONEN, O.
SILKE, B. *see* THAM, T. C. K.
SILKE, B., MCPARLAND, G., WHYTE, P., YOUNG, S., WYLIE, S., ANDERSON, V., SHEIK, V. & SCOTT, M. E. Accuracy and reproducibility of continuous noninvasive blood pressure determination (Finapres) during pharmacodynamic intervention, 540P
SIMPSON, S. *see* RICHARDS, R.
SINGH, S. *see* SUMMERS, Q. A.
SINZINGER, H., RAUSCHA, F., O'GRADY, J. & FITSCHA, P. Prostaglandin I_2 and the nitric oxide donor molsidomine have synerginistic effects on thromboresistance in man, 289
SIROTA, L. A. *see* KUDRIAKOVA, T. B.
SKOVSTED, B. *see* ENGEL, T.
SLOVIC, D. *see* SENNESAEL, J.
SMITH, D. A. *see* HUMPHREY, M. J.
SMITH, D. A. *see* NEWLANDS, A. J.
SMITH, H. *see* DOLBEN, J.
SNAPE, A. *see* WALDEN, R. J.
SNYMAN, J. R. *see* SOMMERS, DE K.
SOARES-DA SILVA, P., FERNANDES, M. H. & PESTANA, M. Levodopa and gamma glutamyl-L-dopa as precursors for dopamine in human renal tissues, 539P
SOHAIL, S. *see* MILLSON, D.
SOHAIL, S. *see* VENTRESCA, G. P.
SOMMERS, DE K., MEYER, E. C., VAN WYK, M., MONCRIEFF, J., SNYMAN, J. R. & GRIMBEEK, R. J. The influence of codeine, propantheline and metoclopromide on small bowel transit and theophylline absorption from a sustained-release formulation, 305
SONDHEIMER, S. J. *see* FREEMAN, E. W.
SPATENKA, J. *see* DASHWOOD, M. R.
SPRING, J., CLAGUE, J. & IND, P. W. A comparison of the effects of salmeterol and salbutamol in normal subjects, 139
STANFORD, C. F. *see* ADAIR, C. G.
STANFORD, C. F. *see* NUGENT, A.-M.
STELL, P. M. *see* HOLDING, J. D.
STEWART, G. A. *see* TAYLOR, M. L.
STEWART-LONG, P. *see* MOORE, K.
STIJNEN, TH. *see* PIETERS, M. S. M.
STIRLING, H. *see* BRIDGES, A.
STOLER, J. *see* KRIVOY, N.
STOPHER, D. A. *see* HUMPHREY, M. J.
SUMMERS, Q. A., SINGH, S., HONEYWELL, R. G., RENWICK, A. G. & HOLGATE, S. T. The effect of respiratory manoeuvres and pharmacological agents on the pharmacokinetics of nedocromil sodium after inhalation, 431
SUTTON, J. A. Letter to the Editors: Gerontokinetics – a reply, 667
SUTTON, J. A. *see* GILBURT, S. J. A.
SWAISLAND, A. *see* MILLSON, D. S.
SWAMINATHAN, R. *see* CHAN, J. C. N.
SWEET, C. S. *see* DOIG, J. K.
SWEETLAND, J., LETTIS, S., FOWLER, P. A. & THOMAS, M. Duration of the inhibitory effect of intravenous ondansetron on intradermal 5-HT-induced flare, 565P
SWENY, P. *see* SENNESAEL, J.
SWIFT, R. H., MANT, T. G., HEALD, A., SCIBBERAS, D. G., IMBIMBO, B., MORRISON, P. J. & GOLDBERG, M. R. A study to investigate the safety, tolerance and pharmacodynamics of single rising doses of 1–693,487 (heptylphysostigmine tartrate) in healthy elderly volunteers, 220
SZABADI, E. *see* BOURNE, M.
SZABADI, E. *see* BRADSHAW, C. M.
SZABADI, E. *see* LEUNG, N. K.-C.
SZABADI, E. *see* THEOPHILOPOULOS, N.

TAN, L. B. *see* NG, L. L.
TAYLOR, G. W. *see* ARCHER, C. B.
TAYLOR, M. L., MISSO, N. L. A., STEWART, G. A. & THOMPSON, P. J. The effects of varying doses of aspirin on human platelet activation induced by PAF, collagen and arachidonic acid, 25
TEMPLETON, E. *see* PIRMOHAMED, M.
TEN HOVE, W. R. *see* KROON, C.
THAM, T. C. K., GUY, S., SHANKS, R. G. & HARRON, D. W. G. Dose-dependent α_1-adrenoceptor antagonist activity of the anti-arrhythmic drug, abanoquil (UK-52,046), without reduction in blood pressure in man, 405
THAM, T. C. K., MCCAFFREY, P. M., WHITEHEAD, E. M., RIDDELL, J. G. & SILKE, B. Reproducibility of computer-assisted forearm blood flow measurements using strain gauge plethysmography in healthy volunteers, 543P
THAWLEY, A. R. *see* BRETT, M. A.
THEODOROPOULOS, S. *see* DASHWOOD, M. R.
THEOPHILOPOULOS, N., MCDADE, G., SZABADI, E. & BRADSHAW, C. M. Comparison of the effects of reboxetine and desipramine on the kinetic parameters of the pupillary light reflex in healthy volunteers, 545P
THIOLLET, M., FUNCK-BRETANO, C., GRANG, J.-D., MIDAVAINE, M., RESPLANDY, G. & JAILLON, P. The pharmacokinetics of perindopril in patients with liver cirrhosis, 326
THOMAS, G. *see* BRAIN, S. D.
THOMAS, M. *see* ECKLAND, D. J. A.
THOMAS, M. *see* SWEETLAND, J.
THOMAS, R. U. *see* SAMPSON, A. P.
THOMAS, S. H. L. Accuracy of stroke volume measurement by Sramek-Bernstein impedance cardiography, 544P
THOMPSON, G. G. *see* MCKEE, P. W. J.
THOMPSON, P. J. *see* TAYLOR, M. L.
THOMPSON, P. J. *see* WATKINS, D. N.
THOMSON, A. H. & TUCKER, G. T. Gerontokinetics – a reappraisal, 1
THOMSON, C. *see* SCOTT, A. K.
THOMSON, M., HAYNES, W. G. & WEBB, D. J. A survey of HIV screening procedures for healthy men entering phase I and II clinical trials, 528P
TIJA, J. F. *see* BACK, D. J.
TIMERICK, S. J. B. *see* GROOM, P. J.
TINGLE, M. D., BLEE, M. A. B., COLEMAN, M. D. & PARK, B. K. The use of a novel three-compartment system to investigate cell selective drug toxicity *in vitro*, 216P
TIPPINS, J. R. *see* JANES, S.
TOCHNER, Z. *see* ZIV, I.
TOMLINSON, B., BHATT, S. B., MAK, M. C. & CRITCHLEY, J. A. J. H. Assessment of inotropic effects of dobutamine by systolic time intervals derived from impedance cardiography, 555P
TRILL, A. S., HUTCHINSON, P. J. A.,

JACKSON, S. H. D. & TURNER, P. Views of hospital staff (trained and in training) on the management of hypertension, 241P
TRIMBLE, E. R. *see* O'KANE, M. J.
TRINICK, T. R. *see* O'KANE, M. J.
TROSTER, E. J. *see* SANTOS, S. R.
TSAO, Y. *see* NG, H. W. K.
TUBERT, P., BÉGAUD, B., HARAMBURU, F. & PÉRÉ, J.-C. Letter to the Editors: 'Spontaneous' reporting of suspected adverse drug reactions–a reply, 462
TUCKER, G. T. *see* BARHAM, H. M.
TUCKER, G. T. *see* BLANKSON, E. A.
TUCKER, G. T. *see* BLOOMER, J. C.
TUCKER, G. T. *see* THOMSON, A. H.
TUOMISTO, L. *see* NIEMINEN, M. M.
TURGEON, J. *see* BIRGERSDOTTER, U. M.
TURGEON, N. *see* SAHAI, J.
TURNER, P. *see* TRILL, A. S.
TYNAN, M. B. *see* O'KANE, M. J.

VADASZ, A. *see* KRIVOY, N.
VAN DER MEER, F. J. M. *see* KROON, C.
VAN DER POL, J. M. J. *see* KROON, C.
VAN GRIENSVEN, J. M. T., SEIBERT-GRAF, M., SCHOEMAKER, H. C. & COHEN, A. F. Pharmacokinetics and pharmacodynamics of ACE inhibitors ramipril and ramiprilat, 544P
VAN HAARD, P. M. M. *see* COHEN, A.
VAN LAER, C. *see* HOLDING, J. D.
VAN RIJ, A. M. *see* KENNEDY, J. M.
VAN STEVENINCK, A. L., SCHOEMAKER, H. C., DEN HARTIGH, J., PIETERS, M. S. M., RIJNKELS, J. M., KROON, J. M. & COHEN, A. F. Pharmacodynamics of intravenous temazepam following fast and slow infusion to pseudo steady state, 533P
VAN VLIET-VERBEEK, A. *see* COHEN, A.
VAN WYK, M. *see* SOMMERS, DE K.
VAN ZWIETEN, P. A. *see* BRUNING, T. A.
VANDENBURG, M. *see* SENNESAEL, J.
VANDENBURG, M. J. *see* ALLEN, M. E.
VANDENBURG, M. J. *see* HORTON, R. C.
VAPAATALO, H. *see* NIEMINEN, M. M.
VENNING, G. R. & SCOTT, G. M. S. Meeting report: New drug treatments for HIV infections and AIDS. A review following the Seventh International Conference on AIDS, Florence 16–21 June 1991, 349
VENTRESCA, G. P., CLARE, C., SOHAIL, S. & MILLSON, D. S. Applied potential tomography combined with the hydrogen breath test to assess gastric emptying and oro-caecal transit time in healthy subjects using different meals, 534P
VENTRESCA, P. G., NICHOL, G. M., BARNES, P. J. & FAN CHUNG, K. Effect of frusemide on the induction and potentiation of cough induced by prostaglandin $F_{2\alpha}$, 514
VERPOOTEN, G. A. *see* HALL, S. T.
VERSANO, D. *see* ZIV, I.
VESTAL, R. E. *see* FORD, G. A.
VIANI, A., RIZZO, G., CARRAI, M. & PACIFICI, G. M. The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and the digitoxin in healthy subjects and patients with renal impairment, 299
VIBERTI, G.-C. *see* BARROW, S. E.
VILLADA, J. R. *see* WALLEY, T.
VREEBURG, G. C. M. *see* HOLDING, J. D.

WADE, J. R., MEREDITH, P. A., HUGHES, D. M. & ELLIOTT, H. L. The effect of saturation of ACE binding sites on the pharmacokinetics of enalaprilat in man, 155
WALDEN, R. J., OWENS, C. W. I., GRAHAM, B. R., SNAPE, A., NUTT, J. & PRICHARD, B. N. C. NSAIDs and the control of hypertension: a pilot study, 241P
WALLER, D. G. *see* ASHAN, C. H.
WALLER, P. C. Book review. Medical treatment. The benefits and risks. The complete reference guide to drug treatments, 210
WALLER, P. C. Measuring the frequency of adverse drug reactions, 249
WALLER, P. C., WOOD, S. M., RAWLINS, M. D. & BRECKENRIDGE, A. M. Patterns of spontaneous adverse reaction reporting with angiotensin converting enzyme inhibitors, 242P
WALLEY, T., AKINGBEHIN, T. & VILLADA, J. R. Topical metipranolol and intraocular inflammation – a rechallenge study, 564P
WALLEY, T. J. *see* NG, H. W. K.
WALSH, J. B. *see* MCCORMACK, P.
WALSH, J. B. *see* O'NEILL, D. O.
WARBURTON, D. M. *see* PRESTON, G. C.
WARD, C. *see* ORCHARD, M. A.
WARD, S. A. *see* EDWARDS, G.
WARD, S. A. *see* WINSTANLEY, P. A.
WARN, P. A. *see* WINSTANLEY, P. A.
WARRELL, D. A. *see* WINSTANLEY, P. A.
WARRINGTON, S., DEBBAS, N., LEWIS, Y. & JOHNSON, A. Efficacy of a lignocaine spray in reducing sensitivity of the penis, 571P
WARRINGTON, S. J. & ANKIER, S. I. Double-blind placebo controlled evaluation of benidipine in mild to moderate essential hypertension, 529P
WARUIRU, C. M. *see* WINSTANLEY, P. A.
WATKINS, D. N., BADCOCK, N. R. & THOMPSON, P. J. Letter to the Editors:Itraconazole concentrations in airway fluid and tissue, 206
WATKINS, W. M. *see* WINSTANLEY, P. A.
WATSON, N. & WYLD, P. J. The importance of general practitioner information in selection of volunteers for clinical trials, 197
WATT, A. H. Letter to the Editors: Spontaneous reporting of suspected adverse drug reactions, 461
WATTS, D. A. *see* GROOM, P. J.
WEATHERLEY, B. *see* PECK, R. W.
WEATHERLEY, B. C. *see* ROLAN, P. E.
WEATHERLEY, B. C. *see* YUEN, A. W. C.
WEAVER, R. *see* NEWLANDS, A. J.
WEBB, D. J. *see* THOMSON, M.
WEBBER, I. R., PETERS, W. H. M. & BACK, D. J. Cyclosporin metabolism by human gastrointestinal mucosal microsomes, 663
WEINSTOCK, L. *see* FREEMAN, E. W.
WELDON, M. *see* SEYMOUR, R. A.
WELLER, C. *see* BOWES, S. G.
WELLER, C. *see* O'NEILL, C. J. A.
WELLS, J. E. *see* ROBSON, R. A.
WERE, J. B. *see* WINSTANLEY, P. A.
WHEELDON, N. M., MCDEVITT, D. G. & LIPWORTH, B. J. Evaluation of *in vivo* partial β_1/β_2-agonist activity: a dose-ranging study with carteolol, 411
WHEELDON, N. M., MCDEVITT, D. G. & LIPWORTH, B. J. Evaluation of the selectivity of antagonist and partial agonist effects of celiprolol in man, 528P
WHELAN, E. *see* ZHOU, H.-H.
WHITEHEAD, E. M. *see* THAM, T. C. K.
WHITEMAN, P. D. *see* PECK, R. W.
WHITING, P. H. *see* MCCLAREN, J.
WHYTE, P. *see* SILKE, B.
WIJAYAWARDHANA, P. *see* CROME, P.
WILD, M. J., BACK, D. J. & RUDLAND, P. S. Metabolism of

contraceptive steroids by human endometrial tissue and an endometrial cell-line (HEC-1A) *in vitro*, 216P
WILDER-SMITH, C. H., HALTER, F., HÄCKI, W. & MERKI, H. S. pH feedback controlled infusions of ranitidine are no more effective than fixed-dose infusions in reducing gastric acidity and variability in antisecretory responses, 487
WILKINS, W. E. *see* ARNOLD, J. D.
WILIAMS, G. T. *see* ARNOLD, J. D.
WILLIAMS, P. E. O., MUIRHEAD, G. J., SERINI, D., ROUSSEAU, F. S. & HOOKER, M. Pharmacokinetics of 2-flurodideoxycytidine (FddC) in patients with AIDS or AIDS-related complex (ARC), 219P
WILLIAMS, R. *see* MORE, K.
WILLIAMS, T. J. *see* SCIBERRAS, D. G.
WILSHER, N. E. *see* PAGE, K. M.
WILSON, C. G. *see* GREAVES, J. L.
WILSON, J. A. *see* HOLDING, J. D.
WINSHIP, K., HEPBURN, D. & LAWSON, D. H. The review of medicines in the United Kingdom, 583
WINSTANLEY, P. A. & WATKINS, W. M. Pharmacology and parasitology: integrating experimental methods and approaches to falciparum malaria, 575
WINSTANLEY, P. A., NEWTON, C. R. J. C., PASVOL, G., KIRKHAM, F. J., MBERU, E., PESHU, N., WARD, S. A., WERE, J. B., WARRELL, D. A. & MARSH, K. Prophylactic phenobarbitone in young children with severe falciparum malaria: pharmacokinetics and clinical effects, 149
WINSTANLEY, P. A., WATKINS, W. M., NEWTON, C. R. J. C., NEVILL, C., MBERU, E., WARN, R. A., WARUIRU, C. M., MWANGI, I. N., WARRELL, D. A. & MARSH, K. The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria, 143
WISSER, H. *see* MEESE, C. O.
WOJNAR-HORTON, R. E. *see* ILETT, K. F.
WOJNAR-HORTON, R. E. *see* LEBEDEVS, T. H.
WOLF, D. *see* LEONHARDT, A.
WONG, W. *see* BIRGERSDOTTER, U. M.
WOOD, A. J. J. *see* ZOU, H.-H.
WOOD, J. K. *see* CAHILL, M.
WOOD, S. M. *see* WALLER, P. C.
WOODHOUSE, K. W. *see* ARNOLD, J. D.
WOODS, F. R. *see* BLOOMER, J. C.
WOODS, H. F. *see* BARHAM, H. M.
WORM, J. *see* HALLAS, J.
WRIGHT, P. M. C. *see* DUNDEE, J. W.
WRIGHT, T. *see* HALL, S. T.
WYLD, P. J. *see* WATSON, N.
WYLIE, S. *see* SILKE, B.

YACOUB, M. *see* CHESTER, M. R.
YACOUB, M. H. *see* LUU, T. N.
YANG, J. *see* DUNDEE, J. W.
YAPP, P. *see* ILETT, K. F.
YAPP, P. *see* LEBEDEVS, T. H.
YATTOO, G. N. *see* KHUROO, M. S.
YORK, M. *see* ECKLAND, D. J. A.
YOUNG, I. *see* NUGENT, A. M.
YOUNG, S. *see* SILKE, B.
YUEN, A. W. C., LAND, G., WEATHERLEY, B. C. & PECK, A. E. Sodium valproate acutely inhibits lamotrigine metabolism, 511

ZARGAR, S. A. *see* KHUROO, M. S.
ZERKOWSKI, H.-R. *see* BRODDE, O.-E.
ZHOU, H.-H., WHELAN, E. & WOOD, A. J. J. Lack of effect of ageing on the stereochemical disposition of propranolol, 121
ZIV, I., VERSANO, D., IZRAELI, M. R. S., ALMOG, S., ALHALEL, A., ALKALAY, M., MENAHEM, S. & TOCHNER, Z. Prevention of peripheral side-effects of transdermal hyoscine by adjunctive therapy with low dosage of pyridostigmine, 507
ZUGAIB, M. *see* SANTOS, S. R.

SUBJECT INDEX

This index was compiled from the keywords

(P = proceedings)

566 C80, 534P
882 C 568P
α-adrenoceptor agonist, 405
α_1-adrenoceptor stimulation, 333
Abanoquil, 405
Abbott-73001, 541P
Absorption, 534P
Absorption interactions, 346
ACE induction, 155
ACE inhibitors, 242P, 544P, 553P
Acetylsalicylic acid, 33
Acipimox, 451
Acitretin, 187
Adenosine, 83
Adenosine A_1-receptor antagonist, 238P
Adverse drug interactions, 539P
Adverse drug reactions, 61, 242P, 249, 461, 462
Adverse renal effects, 385
Aerosol, 641
Age, 121, 235P, 245P, 550P
Aged, 167
Ageing, 83, 299
AIDS, 219P, 349
Airway permeability, 337
Airways, 645
Alcohol, 245P
Aldrin, 226P
Alpha-glucosidase, 225P
Alprazolam, 107
Alzheimer's disease, 220P
Ambient temperature, 458
Ambulatory blood pressure monitoring, 530P
Amiloride, 329
Aminoglycosides, 217P
5-aminosalicylic acid, 179
Amitriptyline, 245P, 570P, 617
Amlodipine, 219P
Amodiaquine, 212P
Amoxapine, 670P
Anabasine, 230P
Analgesics, 357
Angiotensin I radioimmunoassay, 253
Angiotensin I-converting enzyme inhibition, 253
Angiotensin II, 554P
Angiotensin II antagonist, 542P
Angiotensin converting enzyme, 161
Angiotensin converting enzyme inhibition, 326
Angiotensin converting enzyme inhibitors, 93, 242P
Antacids, 115
Antiarrhythmic, class III, 532P
Antibiotics, 551P
Anticoagulant, 541P
Anticoagulation, 467
Antidepressant, 545P, 589
Antigenicity, 212P
Antimuscarinic, 309
Antimuscarinic drug, 228P
Antiprotozoal drug, 534P
Anxiety, 101
Apoprotein, 233P
Applied potential tomography, 534P
Arachidonic acid, 25, 224P
5-ASA, 179
Aspirin, 25
Aspirin esterases, 395
Aspirin tablets, 395
Asthma, 129, 239P, 439, 653
Atenolol, 528P
Atopic asthma, 423
Atopic dermatitis, 566P
Atrial fibrillation, 531P
Atrial flutter, 531P
Atrial natriuretic factor, 167
Atropine, 473
Autoantibody, 183
Autoinduction, 611
Autonomic function, 570P
Autonomic nervous blockade, 473
Avena sativa, 244P
Azithromycin, 551P

β-adrenoceptor agonist, 528P
β_2-adrenoceptor agonists, 129
β-adrenoceptor antagonist, 528P
β_1-adrenoceptor antagonists, 269
β-adrenoceptors, 83, 417
β-endorphin, 89
Behavioural effects, 293
Bendroflumethiazide, 224P
Benidipine, 529P
Benzodiazepines, 641
Biliary manometry, 477
Binding, 299, 653
Bioavailability, 51, 226P, 236P
Blood, 319
Blood flow, 117, 543P
Blood pressure, 107, 333, 540P, 560P
Blood vessels, 529P
Bradykinin, 566P
Breast milk, 204
Brofaromine, 245P
Bronchodilator, 139
Budesonide, 645
Buffered aspirin, 395
Bumetamide, 224P
Buspirone, 555P

CGP 38560A, 253
CNS effects, 261
CYP1A2, 213P
Calcitonin gene-related peptide, 247P
Calcium, 161
Calcium antagonist, 236P
Calcium antagonists, 269, 467
Calcium channel antagonist, 242P
Calcium entry blocking drug, 529P
Camostate, 535P
Cancer chemotherapy, 200, 243P
Capsaicin, 514
Captopril, 167
Carbamazepine, 111, 183, 547P, 551P, 611
Carbamazepine-10-11-diol, 611
Carbamazepine-10, 11-epoxide, 611
Carbocysteine, 536P
Carcinogenic heterocyclic amines, 213P
Cardiac transplantation, 417
Carteolol, 411
Catell 16PF, 107
Cefuroxime, 226P
Celiprolol, 528P
Cerebral blood flow, 555P
Cerebral infarction, 467
Cerebral perfusion, 401
Cetirizine, 445
Children, 45
Chondroprotection, 357
Cicletanine, 530P
Cilazapril, 553P
Cimetropium bromide, 228P
Cisplatin, 75
Cisplatin-albumin complex, 75
Clinical pharmacology, 365
Clonidine, 261
Codeine, 45, 305
Cognitive deficit, 546P
Cognitive function, 111
Collagen, 25
Committee on the Review of Medicines, 583
Complex formation, 115
Congenital heart disease, 323
Congestive heart failure, 223P
Contraceptive pill, 11
Contraceptive steroids, 216P
Coronary artery bypass grafting, 222P
Cortisol, 231P
Cough, 514
Coumarin, 214P, 313
Coumarin derivatives, 553P
Cyclamate, 238P
Cyclohexylamine, 238P
Cyclosporin, 39
Cyclosporin A, 663
Cystic fibrosis, 653
Cytochrome P450, 218P, 228P
Cytochrome P4502D6, 234P, 521
Cytochrome P-4503A, 663
Cytochrome P450IA, 233P
Cytochrome P450IA2, 233P
Cytochrome P450IID6, 277P
Cytochrome P450IIIA, 226P

Denbufylline, 235P, 236P
Desipramine, 17, 545P
Diabetes, 242P, 531P, 562P
Diazepam, 244P, 299, 549P, 570P, 244
Dideoxyinosine, 319

Digit substitution, 570P
Digital electronic sphygmomanometers, 560P
Digitoxin, 299, 550P
Digoxin, 203
Dipipanone, 449
Diuretics, 329
Diurnal variations, 179
Dobutamine, 555P
Dopamine, 539P
Dose-response, 293, 405, 487
Dothiepin, 635
Dothiepin-S-oxide, 635
Doxazosin, 558
Drug interactions, 115, 275
Drug metabolism, 313
Drug therapy, 557P
Drug toxicity, 216P
Drug treatment, 467
Drugs in milk, 501

EEG brain mapping, 589
Ebastine, 244P
Eflornithine, 535P
Elderly, 220P
Emesis, 200, 221P
Enalaprilat, 155
Enantiomers, 51, 517
Endometrial tissue, 216P
Endothelial-dependent relaxation, 222P
Endothelin, 117
Endothelin-3, 529P
Endothelium derived relaxing factor, 289, 531P, 289
Enpiroline, 517
Epidermis, 187
Epilepsy, 111, 547P, 549P
Erythromycin, 217P
Ethnic group, 214P
Euglycaemic clamp, 537P
Evoked potential, 220P
Exercise, 89

FK453, 238P
Faecal blood loss, 33
Falciparum malaria, 575
Famotidine, 193
Feedback infusion pump, 487
Felodipine, 226P
Fibrinogen binding site, 11
Finapres, 540P
First-pass metabolism, 51
Fish oil, 531P
Flare, 117
Flare response, 546P
Flecainide, 275
Flosequinan, 557P
Fluoxetine, 245P, 536P
Flurbiprofen, 369, 385
Flurbiprofen enantiomers, 377
2-fluorodideoxy cytidine, 219P
2-fluoro-17α-ethinyl-17β-oestradiol, 231P
Food, 179, 226P, 236P, 534P, 536P
Formulation, 495, 547P
Free walking speed, 246P
Frusemide, 514

GAZT, 190
GM-CSF, 423
GR68755, 546P
Gamma scintigraphy, 603
Gastric emptying, 534P
Gastrin, 487
General practitioner, 69, 197
Gerontokinetics, 1, 463
Glomerular filtration, 385
Glucuronide formation, 511
Glucose, 217P
Good clinical practice, 463
Growth hormone, 563P
Gut wall metabolism, 663

H_1-receptor antagonist, 445
H_2-receptor antagonist, 487
HIV infection, 349
HIV screening, 568P
HMG CoA reductase inhibitor, 553P
Haemodynamic responses, 261
Halofantrine, 517
Haloperidol, 230P
Hazards, 125
Head and neck cancer, 75
Health care, 365
Healthy, 197
Heart failure, 167, 224P, 269, 543P
Heart rate, 107
Heparin, 541P
Hepatic function, 560P
Hepatic microsomes, 213P
Hepatic uptake, 219P
Heptylphysostigmine, 220P
High dose, 342
Hirudin, 524
Histamine, 117, 337, 645
Histamine H_1-receptor antagonist, 244P
Histamine H_2-receptor antagonist, 193, 229P, 556P
Homeopathy, 244P
Hospital admission, 39, 61
5-HT_2-receptor antagonist, 281
5-HT_3-receptor antagonist, 221P
Human, 417
Human allergic rhinitis, 445
Human cardiac β_1- and β_2-adrenoceptors, 269
Human psychopharmacology, 589
Human right atrium, 269
Humans, 17
Hydrogen breath test, 534P
Hydroxylation, 313
5-hydroxytryptamine, 536P, 546P, 554P, 565P
5-hydroxytryptamine-like agonist, 538P
5-hydroxytryptamine$_{1A}$ partial agonist, 555P
5-hydroxytryptamine$_3$ receptor antagonist, 546P
Hyoscine, 507
Hyperlipidaemia, 451
Hypersensitivity, 183
Hypertension, 224P, 238P, 241P, 529P, 530P, 562P
Hypotension, 532P

ICI 170, 809, 281
Impedance cardiography, 555
Infants, 45
Inhaled, 342
Inhalers, 439
Insulin, 537P
Interaction, 217P, 511, 551P, 553P, 557P, 558P
Interindividual variability, 17
Intervention, 69
Intestinal absorption, 39
Intestinal inflammation, 240P
Intramuscular, 617
Intraocular inflammation, 564P
Intraocular pressure, 603
Intrinsic heart rate, 89
Ipecacuanha, 221P
Iron, 115
Itraconazole, 206

Kalladin, 566P
Kidney failure, 93
Kidney metabolism, 190

L-691, 121, 532P
L-acetyl-carnitine, 220P
LV function, 333
Lacidipine, 537P, 559P, 560P
Lamotrigine, 511
Late potentials, 563P
Leading article, 125
Leukaemia, 552P
Leukocytes, 423
Leukotriene B_4, 645
Leukotriene E_4, 566P
Leukotrienes, 423
Levodopa, 538P
Lignocaine, 234P
Lignocaine spray, 571P
Lipoprotein (a), 562P
Lisinopril, 161
Liver, 17
Liver cirrhosis, 326, 550P
Local administration, 33
Lofepramine, 232P
Loratidine, 567P
Losartan, 542P
Lymphocyte, 329

M/P ratio, 510
MKS 492, 239P
MPTP, 230P
Magnesium, 329
Malaria, 143, 149, 212P, 517, 575
Man, 155
Mast cells, 117
Mecillinam, 629
Medicines Control Agency, 583
Mefloquine, 517
Mental arithmetic, 107
Mephenytoin, 665
6-mercaptopurine, 552P
Metabolism, 121, 214P, 228P, 229P, 231P, 319, 521, 536P, 617
Metabolite formation, 369
Methyl anabasine, 230P
Metipranolol, 564P
Metoclopramide, 305
Midazolam, 217P, 532P

Mifentidine, 229P
Miglitol, 225P
Migraine, 401
Milk, 346, 635
Milk:plasma ratio, 501
Model, 501
Molsidomine, 289
Mood effects, 293
Morphine, 45, 215P
Motion-sickness, 507
Moxonidine, 261
Myocardial infarction, 563P
N-demethylation, 215P
N-sulphation, 17
NSAID, 33
Nabumetone, 33
Nadolol, 528P
Nasal airway resistance, 445
Natriuresis, 385
Nedocromil sodium, 431
Neonates, 323
Neurotoxin, 230P
Newborn, 561P
Nicotinic acid, 451
Nifedipine, 161, 214P, 477, 558P
Nitrendipine, 51
Nitric oxide (NO), 289
Nitrolingual spray, 223P
Nizatidine, 528P
Non-compliance, 61
Non-insulin dependent diabetes mellitus, 531P, 552P
Non-steroidal anti-inflammatory drugs, 33, 240P, 241P, 357
Noradrenaline, 554P
Nordothiepin, 635
Nordothiepin-S-oxide, 635
Norfloxacin, 115
Normal subjects, 369
Noroxycodone, 617
Nucleoside analogue, 568P
Nucleotide levels, 228P

O-demethylation, 45
Ofloxacin, 346
Ondansetron, 200, 565P
Ophthalmic drug delivery, 603
Ophthalmic inserts, 603
Oral, 617
Oral progesterone, 293
Oral-caecal transit time, 305, 534P
Osteoarthritis, 357
Oxycodone, 617
Oxymorphone, 617

P300, 220P
P450 2A6, 313
P450 2a–6, 313
$PGF_{2\alpha}$, 514
Pancreatic polypeptide, 487
Paracetamol (acetaminophen), 309, 552P
Parasitology, 575
Parkinson's disease, 569P
Parkinsonism, 246P
Paroxetine, 227P, 521
Partial agonist activity, 411
Peptic ulcer, 240P
Perindopril, 93, 327
Personality, 101
Personality profile, 107
Pharmacodynamics, 193, 220P, 237P, 245P, 487, 495, 533P, 540P, 544P, 559P, 560P, 623
Pharmacogenetics, 275
Pharmacokinetics 51, 93, 143, 149, 155, 179, 187, 193, 214P, 216P, 219P, 235P, 236P, 237P, 238P, 309, 369, 377, 449, 495, 544P, 559P, 560P, 568P, 575, 617, 623, 629, 641, 658, 661
Phase I trials, 568P
Phase II trials, 568P
Phenobarbitone, 149
Phenotyping, 665
Phentolamine, 473
Phenylephrine, 405
Pilocarpine, 603
Pindolol, 411, 561P
Pirenzepine, 309, 528P
Pituitary adrenal function, 538P
Pivmecillinam, 629
Placebo, 07, 342
Placental transfer, 629
Plasma concentrations, 293
Plasmodium falciparum, 517
Platelet activating factor, 25, 567P, 645
Platelet aggregation, 25, 281
Platelet fibrinogen receptor, 3
Platelet function, 541P
Platelet hyperactivity, 224P
Platelets, 11, 17, 161
Polyamine metabolism, 535P
Post-cholecystectomy syndrome, 477
Post-marketing surveillance, 567P
Postoperative pain, 395
Precipitate ejaculation, 571P
Prednisolone, 495
Pregnancy, 561P, 629
Prescribing, 69
Probenecid, 431
Product licence, 583
Propantheline, 305
Propranolol, 121, 473
Prostaglandin E_1, 323
Prostaglandin I_2 (PGI_2), 289
Protein binding, 377, 553P
Protein supplement, 658
Proximal tubular cells, 217P
Psoriasis, 566P
Psychometry, 589
Psychomotor tests, 111
Psychophysiology, 589
Pupil diameter, 603
Pupil response, 281
Pupillary light reflex, 458, 545P, 549P
Pyridostigmine, 507
Pyrimethamine, 143

Quinidine, 275
Quinidine methylenedioxyphenyl, 521

RP 61969, 553P
Radionuclide cardiography, 473
Ramipril, 544P
Ramiprilat, 544P
Ranitidine, 487
Reboxetine, 545P
Rectal administration, 45
Relative maternal dose, 635
Renal failure, 299
Renal function, 237P, 559P, 562P
Renin inhibition, 253
Respiratory manoeuvres, 431
Risks, 125
Roxatidine, 556P

Saccadic eye movements, 549P
Salbutamol, 139, 342
Salicylic acid, 299
Salivary secretion, 309
Salmeterol, 342
Salmeterol hydroxynaphthoate, 139
Sales representative, 69
Saphenous vein, 222P
Sedative, 244P
Selection, 101, 197
Senile dementia, 220P
Sensation seeking, 101
Serum albumin, 567P
Side-effects, 507
Simvastatin, 538P
Sinemet CR, 569P
Small bowel transit, 305
Smoking, 193
Smooth muscle, 83
Sodium cromoglycate, 337
Sodium valproate, 511
Sperm motility, 203
Sphincter of Oddi syndrome, 477
Spontaneous reporting, 61, 461
Sramek-Bernstein impedance cardiography, 544P
Steady-state pharmacokinetics, 611
Stereoselective, 121, 369, 377
Stereoselectivity, 51
Steroid hydroxylation, 215P
Strain gauge plethysmography, 543P
Stress, 538P
Stroke volume, 544P
Stud 100, 571P
Sublingual, 623
Substance P, 247P
Subtypes, 417
Suggestion, 107
Sulindac, 212P
Sulphadoxine, 143
Sulphoxide drugs, 212P
Sumatriptan, 401, 538P
Suriclone, 550P
Sustained-release formulation, 305
Sympathetic reflex, 458
Systolic time intervals, 555P

Takeda AA-2414, 541P
Tamoxifen, 234P
Temazepam, 204, 533P, 641
Temperature, 549P
Terbutaline, 439
Theophylline, 305, 653
Third molar surgery, 395
Three-compartment system, 216P
Thrombin, 524
Thrombolysis, 467
Thromboresistance, 289
Thromboxane biosynthesis, 562P

Thromboxane receptor antagonist, 541P
Time-course, 589
Tissue ACE, 155
Tolerability, 589
Tolerance, 111, 487, 549P
Toxicity, 183
Trandolapril, 237P
Transdermal, 507
Treatment, 357
Tricyclic antidepressant, 232P
Tropical pharmacology, 573
UK-52,046, 405
UK-52, 831, 236P
Uraemia, 377
Vagal tone, 333
Variability, 653
Vasoactive intestinal peptide, 222P
Veins, 83
Venlafaxine, 589
Verapamil, 531P, 623
Vigabatrin, 548P
Volunteer, 197
Volunteers, 101
Walking ability, 167
Warfarin, 313P, 557P
Xamoterol, 543, 539P
Yoghurt, 346
Zidovudine, 190, 658
Zinc, 115